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Abstract 
XRN2 is an essential nuclear 5’  3’ exoribonuclease that is involved in quality control, processing 
and degradation of RNAs, such as rRNA, snRNA and miRNAs. Recently, C. elegans XRN2 was 
discovered to exist in a stable complex with PAXT-1. Binding to XRN2 is mediated by PAXT-1’s 
DUF3469/XRN2 binding domain (XTBD). Whereas binding of the XTBD confers stability on XRN2 
similar to observations made for yeast Rai1 – Rat1 complexes, kinetic analysis using the Michaelis-
Menten model does not show any contributions to catalytic activity by PAXT-1. However, XRN2 alone 
processively degrades small RNAs, like its paralog XRN1, but shows no release activity for miRNAs off 
AGO, even when bound to PAXT-1. Here we show the XTBD to be a general binding domain for 5’  
3’ exoribonucleases 2 and present the crystal structure of the XTBD – XRN2 complex. Whereas the 
XTBD serves as a general adapter to XRN2, XRN1 binding is excluded due to sterical hindrance. 
Strikingly, a single point mutation in PAXT-1 Tyr56 completely abrogates binding to XRN2 in vitro and 
in vivo. Using CRISPR to generate endogenous PAXT-1 Tyr56 to Ala mutations, phenotypes identical 
to paxt-1 null mutant worms are observed. Remarkably, paxt-1null mutant worms can be rescued by 
an unrelated XTBD-containing protein from humans, CDKN2AIPNL, which confers stability to XRN2 
by formation of a chimeric complex in vivo. We conclude that XRN2 uses a similar mechanism for 
substrate binding and processive degradation as XRN1 and that PAXT-1 confers stability to the 
nuclease complex by binding through its XTB domain. Moreover, the XTBD serves as a general 
binding adapter for the XRN2 nuclease family, yet excluding XRN1 binding.  
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I Introduction  
1 RNA metabolism 
Ribonucleic acids (RNA) are molecules that play an important role in crucial metabolic functions 
such as protein synthesis and its regulation. The molecule itself is built by a multiple of connected 
mononucleotides. These consist of a ribofuranose moiety linked with one of four bases on the 1’ 
carbon, assembling to adenosine (A), cytidine (C), guanosine (G) and uridine (U) and a phosphate 
group at the 5’ carbon (Westheimer, 1987). Unlike deoxyribonucleic acid (DNA), RNA mostly exists as 
a single strand, however forms secondary structures by base-pairing with itself (Holley et al., 1965; 
Mathews et al., 2004; Tinoco and Bustamante, 1999). In certain circumstances RNAs also form 
intermolecular duplexes, e.g. miRNA – mRNA or miRNA passenger – guide duplexes (Bushati and 
Cohen, 2007; Krol et al., 2010). Until two decades ago the RNA field was mainly focused on RNA 
molecules supporting and facilitating protein synthesis. Five major RNA species play a crucial role, 
messenger RNA (mRNA), ribosomal RNA (rRNA), small nuclear RNA (snRNA), transfer RNA (tRNA) and 
ribozymes/RNase P. However, with the discovery of previously unknown non-coding RNAs (ncRNA) 
such as micro-/small interfering- and Piwi-interacting RNAs (miRNA/siRNA/piRNA) as well as long 
non-coding RNAs (lncRNA), the field of RNA rapidly gained attention (Brosius and Tiedge, 2004; 
Girard et al., 2006). This is because only about 2% of the genome codes for protein-coding mRNAs 
and until recently the remainder was considered “junk DNA” (Frith et al., 2005; Mattick, 2001; Ohno, 
1972). Remarkably, with new RNA species emerging it becomes evident, that some of the so called 
“junk DNA” serves coding for functional RNAs yet do not code for proteins (Kapranov et al., 2010). 
While RNAs execute many important functions, their biogenesis, processing and decay is 
dependent on RNA nucleases (RNases) (Miki and Großhans, 2013; Nagarajan et al., 2013; Yang, 2011; 
Yang et al., 2006). This class of enzymes cleaves phosphodiester bonds of the ribonucleic phosphate 
backbone and can be regarded as molecular machines that solely degrade the RNA polymer (Yang, 
2011). However such a simplified view does not account for the many essential biological tasks 
RNases are involved in, such as rRNA maturation, splicing, gene silencing, and viral defense (Krol et 
al., 2010; Li et al., 2015; Miki and Großhans, 2013). Thus, understanding RNases and their functional 
relationship with RNAs as well as the underlying molecular mechanism are important to understand 
fundamental processes of life. Expression of a gene, meaning the transformation of the genetic code 
into functional molecules, is such a fundamental process and illustrates the functional complexity of 
RNAs and RNA nucleases (Figure 1). It starts with transcription, generating the nascent mRNA, and 
RNA nucleases CPSF as well as XRN2 make important contributions in mRNA cleavage and 
transcription termination, respectively (Hsin and Manley, 2012). Concomitantly, introns are excised 
through a process called splicing, which involves ribozymes exhibiting RNase activity to support 
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maturation of the mRNA (Wachtel and Manley, 2009; Will and Lührmann, 2011). Subsequently, the 
ribosome, a molecular machine consisting of rRNAs and proteins, translates the mRNA sequence to 
synthesize a polypeptide chain, which then assumes a functional three-dimensional fold (Ben-Shem 
et al., 2011; Klinge et al., 2011; Rabl et al., 2011). rRNAs themselves heavily depend on, for example, 
small nucleolar RNAs (snoRNA) and various RNases, such as XRN2, to fully mature to functional 
molecules (Gerbi et al., 2001). Finally the mRNA is degraded by the exosome and/or XRN1, which is 
initiated by various mechanisms such as decapping, deadenylation, non-sense mediated decay 
(NMD) or RNA interference (RNAi) (Figure 1) (Garneau et al., 2007; Krol et al., 2010; Schoenberg, 2011). 
Thus RNases are more specialized and appear more versatile than pure scavenger RNA nucleases 
would suggest. Especially the RNase XRN2 acts on various different, yet important RNAs and 
understanding this molecular machine on a functional and molecular level will thus expand our 
understanding of many key biological processes (Miki and Großhans, 2013; Nagarajan et al., 2013). 
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Figure 1: The scheme shows the various different stages of transcription and translation, in which RNases are 
involved (drawing taken from Houseley and Tollervey, 2009). 
 
1.1   RNases and Their Role in Eukaryotic Gene Expression of Proteins 
The messenger RNA conveys the genetic information from the nucleus to the cytoplasm and serves 
as a blueprint for protein synthesis (Carmody and Wente, 2009; Khorana et al., 1966; Nirenberg et al., 
1966). Its biogenesis starts with the transcription of DNA by RNA polymerase II (RNAP II) (Bentley, 
1999; Maniatis and Reed, 2002). Transcription is initiated by formation of a pre-initation complex 
(PIC), harboring transcription factors, co-activators and chromatin-remodeling complexes, at the 
promoter of a gene, upstream of transcribed DNA (Kim et al., 1997). This complex forms the 
transcription bubble, so that RNAP II binds the DNA and synthetizes an RNA polymer  (Holstege et 
al., 1997; Kim et al., 2000; Wang et al., 1992). RNAP II, a nucleotidyltransferse with 12 subunits, then 
synthesizes a polynucleotide chain by using nucleoside triphosphate substrates (Gnatt et al., 2001; 
Kershnar et al., 1998; Myer and Young, 1998). Moreover, the largest subunit RPB1 of the RNAP II 
holoenzyme contains a carboxy terminal domain (CTD) and RNAP II activity is regulated through the 
CTD phosphorylation state (Hsin and Manley, 2012). For example, transcription factor TFIIH 
associated cyclin-dependent kinase 7 (CDK7) phosphorylates Ser5 of the CTD and releases RNAP II 
from the promoter region to start elongation (Akoulitchev et al., 1995; Feaver et al., 1991; Lu et al., 
1992). Co-transcriptionally, the pre-mRNA is processed by factors loaded onto RNAP II’s CTD as soon 
as it emerges from the RNA exit channel. Its 5’- end is capped with a methylated guanine 
monophosphate (m7GMP), which is linked by a 5’ – 5’ triphosphate bridge to the pre-mRNA to protect 
it from nucleolytic degradation (Garneau et al., 2007; Shatkin, 1976). Furthermore, introns, non-
coding sequences, are excised from the pre-mRNA and flanking exons are joined together in a 
process referred to as splicing (Wachtel and Manley, 2009; Will and Lührmann, 2011). The complex 
process of splicing is carried out by the spliceosome, made up by protein complexes containing non-
coding snRNAs U1, U2, U4, U5 and U6, called small ribonucleic proteins (snRNPs). These snRNPs 
transiently interact with each other, dependent on the specific splicing step. In a first step the 
intronically encoded splice site is recognized, followed by the nucleophilic attack of the branch point 
adenosine forming the intron lariat. Subsequently, the lariat is cleaved and flanking exons end-
joined. This reaction is catalyzed by the snRNAs U2 and U6, as they show Mg2+ dependent 
endonuclease activity and are referred to as ribozymes (Valadkhan et al., 2007). U2 and U6 form a 
complex through extensive base-pairing and the AGC triad as well as the adjacent ACAGAGA box of 
U6 are crucial for catalysis (Dayie and Padgett, 2008; Hilliker and Staley, 2004; Lesser and Guthrie, 
1993; Wachtel and Manley, 2009). However protein-free splicing reactions are slow, suggesting that 
proteins must be involved in catalysis or at least stimulate ribozyme activity (Valadkhan et al., 2007). 
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Remarkably, the crystal structure of a domain of Prp8, interacting with U2 and U6 at the core of 
splicing catalysis, revealed an RNase H-like fold and Mg2+ binding capabilities (Pena et al., 2008; 
Ritchie et al., 2008; Yang et al., 2008). Even though the RNase H-like domain is truncated and lacks 
some key catalytic residues, point mutations at Prp8’s active site have severe viability defects, 
suggesting a direct engagement in catalysis (Pena et al., 2008). To guarantee for a correct exon 
sequence, splicing is carried out co-transcriptionally and the RNAP II CTD in part recruits splicing 
factors to do so. In a final step, the capped- and spliced- pre-mRNA is endonucleolytically excised off 
the RNAP II – DNA complex and polyadenylated at its 3’-end by CPSF (cleavage/polyadenylation 
specificity factor) and polyadenylate polymerase (PAP), respectively (Balbo and Bohm, 2007; Murthy 
and Manley, 1995). The CPSF is a tetrameric protein complex with subunit CPSF-160 recognizing and 
binding the polyadenylation signal (AAUAAA) and CPSF-73 mediating cleavage (Mandel et al., 2006). 
CPSF-73 belongs to the β-CASP nucleases adapting a metallo-β-lactamase fold and hydrolyzes 
phosphodiester bonds in RNA or DNA. Remarkably, hydrolysis depends on two Zn2+ ions and works 
either endo- or 5’- exoribonucleolytically. Unique zinc-dependency of the β-lactamase class enzymes 
is probably mediated by a high number of histidines in the catalytic center (Mandel et al., 2006; Yang, 
2011). Subsequently, the acquired poly(A) tail is bound by different poly(A)-binding proteins (PABP), 
which modulates PAP activity (nuclear PABPN1) (Kerwitz et al., 2003; Kühn et al., 2009; Wahle, 1991) 
and translation (cytoplasmic PABPC) (Gray et al., 2000; Imataka et al., 1998; Otero et al., 1999) as well 
as protecting the 3’- tail from exonucleolytic degradation in vitro (PABPC) (Bernstein et al., 1989; Ford 
et al., 1997; Körner and Wahle, 1997; Wormington et al., 1996). Finally, transcription is terminated 
through a yet not well understood mechanism, however an increasing number of reports indicate 
XRN2 to play an important role (see below) (Brannan et al., 2012; Dengl and Cramer, 2009; El Hage et 
al., 2008; Kim et al., 2004; Luo et al., 2006; Wagschal et al., 2012; West et al., 2004).   
The final transcript is then exported to the cytoplasm and used as a template for translation to 
generate functional proteins (Carmody and Wente, 2009). Accordingly, tRNAs, which are covalently 
bound to one of the 21 amino acids at the 3’-end, pair to the template mRNA with their 
corresponding anti-codon and thus deliver substrates for protein synthesis (Schimmel et al., 1993). 
tRNAs themselves interact with RNases such as RNase Z, RNase P and XRN2 for maturation and 
quality control, respectively (Wichtowska et al., 2013). RNase Z cleave the 3’ trailer and RNase P the 5’ 
leader sequence of the pre-tRNA endonucleolytically. Whereas RNase Z depends on two Zn2+ ions 
and shares similarities to the β-lactamase fold, RNase P is a classical ribozyme using two Mg2+ ions 
for hydrolysis (Kirsebom, 2007; de la Sierra-Gallay et al., 2005). 
Translation, similarly to transcription, follows a heavily regulated and complex initiation-, 
elongation- and termination process (Schmeing and Ramakrishnan, 2009) mainly driven by the 
ribosome. The ribosome, with its major 60 S and 40 S subunits, is a 3.2 MDa RNP and both subunits 
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in turn are complexes of mature rRNAs and various protein subunits. It catalyzes the peptidyl 
transferase reaction by which a polypeptide chain is formed (Ben-Shem et al., 2011; Klinge et al., 
2011; Rabl et al., 2011). The 28 S ribosomal RNA, with its enzymatic activity, is a prime example of a 
ribozyme, which was believed to be an exclusive function of proteins for decades (Kruger et al., 1982; 
Nissen et al., 2000; Voorhees et al., 2009). As such, rRNAs are crucial for protein synthesis and their 
biogenesis as well as quality control is driven by RNases such as XRN2 (see below) (Miki and 
Großhans, 2013; Nagarajan et al., 2013).  
 
1.2 Regulation of Gene Expression Through small RNAs and RNases 
Whereas mRNAs convey information for protein synthesis as described above, non-coding RNA 
(ncRNA) function as scaffolds, guides or exhibit enzymatic activity (Mattick and Makunin, 2006). This 
class of RNA is roughly divided by size into small- and long- ncRNAs (Guttman and Rinn, 2012; Kim et 
al., 2009), with small ncRNAs being capable to regulate gene expression post-transcriptionally 
(Fabian and Sonenberg, 2012; Krol et al., 2010; Peters and Meister, 2007).  
RNA induced gene silencing is a post-transcriptional process by which translation is inhibited 
and/or mRNA degradation is induced (Ecker and Davis, 1986; Fire et al., 1998; Ratcliff et al., 1997). This 
process is driven by small 20 to 25 nt long single stranded RNA molecules, derived from endogenous 
or exogenous RNA precursors. For siRNAs, RNA precursors originate from viral RNA material and serve 
as an antiviral defense mechanism or can be taken up from the environment (C. elegans RNAi by 
feeding) (Hamilton and Baulcombe, 1999; Timmons and Fire, 1998). For miRNAs these precursors are 
RNAP II transcripts, containing a cap-structure as well as a poly(A) tail, that are referred to as primary 
micro RNA (pri-miRNA) (Lee et al., 2002). 
An enzyme complex consisting of DGCR8, a RNA binding protein, and endonuclease Drosha (for 
details see below) bind and cleave the pri-miRNA to a shorter, approx. 70 nt long hairpin RNA called 
precursor miRNA (pre-miRNA) (Denli et al., 2004; Gregory et al., 2004; Lee et al., 2003). Bound by 
exportin 5, the pre-miRNA is exported to the cytoplasm (Bohnsack et al., 2004; Lund et al., 2004; Yi et 
al., 2005) and undergoes its final maturation step by cleavage through Dicer. The endoribonuclease 
Dicer processes not only pre-miRNAs but also exogenous RNA fragments to produce dsRNA 
fragments consisting of a guide-/passenger- or 5p-/3p- strand for siRNA and miRNA, respectively 
(Bernstein et al., 2001; Grishok et al., 2001; Hutvágner et al., 2001; Knight and Bass, 2001). Dicer and 
Drosha are eukaryotic homologs of bacterial RNase III and comprise two active centers to produce 
double stranded RNA fragments. This class of enzymes depend on two metal ions for sequence 
independent cleavage and the catalytic event is thus similar to that of RNase H (Gan et al., 2006). The 
two active sites, built by two aspartates and a glutamate, are aligned to the substrate such that 
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cleavage occurs symmetrically to produce a 2 nt overhang at each strand’s 3’ end. Whereas substrate 
binding is facilitated by a dsRNA binding domain, analysis of the Dicer crystal structure revealed 
additional RNA binding domains. These domains mediate length and structure specificity for 
cleavable substrates to produce Dicer typical dsRNAs with a usual length of approx. 20 nt (Gan et al., 
2006; Macrae et al., 2006; MacRae et al., 2007). Of note, miRNA duplexes contain a bulge, a locus of 
unpaired nucleotides, whereas siRNA duplexes are usually fully complementary. One strand is then 
selected and loaded to an argonaute protein (Aza-Blanc et al., 2003; Khvorova et al., 2003; Schwarz 
et al., 2003). 
The argonaute protein family (AGO) is grouped in three subfamilies, the AGO clade, the Piwi clade 
and the worm specific WAGO clade, with each clade and their respective proteins serving different 
specialized functions (Ender and Meister, 2010; Peters and Meister, 2007). Argonautes have a well 
conserved domain architecture. Whereas its PAZ domain recognizes and binds the 3’- end of the 
selected RNA (Lingel et al., 2003; Yan et al., 2003), its MID domain binds the 5’- phosphate. The Piwi 
domain adopts an RNase H fold, which is – depending on the specific AGO – active and exhibits 
endonuclease activity towards an RNA – RNA duplex (Elkayam et al., 2012; MacRae et al., 2008; Schirle 
and MacRae, 2012; Song et al., 2004). This enzymatic activity relies on the catalytic DEDH motif, which 
coordinates three metal ions similar to transposases (Rivas et al., 2005). Interestingly, human Ago3 
(hAgo3) harbors this catalytic motif, but exhibits no endonucleolytic activity. As the DEDH motif is a 
prerequisite for activity, the presence of two unstructured loops in the N-terminal domain, absent in 
hAgo3, are required to determine an AGO protein to be cleavage-competent, at least in humans 
(Faehnle et al., 2013; Hauptmann et al., 2013; Schürmann et al., 2013). The varying number of different 
AGO proteins reflect the importance of their functional role and different small RNA species may be 
loaded to certain AGOs. Whereas siRNAs are preferably loaded to cleavage-competent AGOs, 
miRNAs are loaded to catalytically inactive forms (Chekulaeva et al., 2011; Fabian et al., 2012; 
Förstemann et al., 2007; Jannot et al., 2008; Mathys et al., 2014; Mi et al., 2008; Okamura et al., 2009; 
Steiner et al., 2007). MiRNA-loaded AGOs bind to the 3’ untranslated region (UTR) of an mRNA by 
imperfect base pairing. Precisely, the miRNA seed-sequence (nt 2 – 8), located on its 5’-end, binds 
the 3’ UTR fully complementary, whereas some nucleotides within its 3’-end do not match the target 
sequence (Lai, 2002; Lee et al., 1993; Lewis et al., 2003; Lim et al., 2005; Wightman et al., 1991). Upon 
binding to the 3’ UTR, the RNA-induced silencing complex (RISC) is formed, including miRNA-AGO 
complex and GW182 protein (AIN-1/2 in C. elegans) mediating translation inhibition and mRNA 
degradation (Chekulaeva et al., 2011; Hammond et al., 2000; Li et al., 2008; Meister et al., 2005; 
Rehwinkel et al., 2005). GW182 is a scaffold protein and recruits the CCR4/NOT effector complex 
through its multiple tryptophan repeats (Braun et al., 2011; Chekulaeva et al., 2011). The deadenylase 
CCR4/NOT acts on the targeted mRNA by translationally repressing it and subsequently initiating its 
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degradation by the exosome due to the loss of the mRNA’s poly(A)- tail (see details below) (Behm-
Ansmant et al., 2006; Chen et al., 2009; Piao et al., 2010). For siRNAs bound by slicing AGO2 however, 
mRNAs are endonucleolytically cleaved and therefore form a suitable substrate for exoribonucleases 
(see details below).  
Taken together, RNPs consisting of argonaute proteins and small non-coding RNAs, fine tune gene 
expression post-transcriptionally and 50% of all mRNAs are predicted to be controlled by this 
mechanism, which is supported by various RNases (Figure 2) (Krol et al., 2010). 
 
Figure 2: The scheme illustrates the multiple steps of miRNAs and siRNAs maturation mediated by Drosha and 
Dicer as well as RNase activity triggered by the RNA-induced gene silencing mechanism (drawing taken from 
Houseley and Tollervey, 2009).  
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2 RNA Degradation by Exoribonucleases 
RNA nucleases are enzymes that execute many vital tasks to ensure cellular viability and protection 
(Yang, 2011). They can be grouped by their mode of action as endoribonucleases cleaving within an 
RNA molecule or as exoribonuclease cleaving from either the 5’- or 3’-end. Alternatively, RNases can 
be grouped by their metal-ion dependencies, which is the requirement of one, two or no metal ion 
for catalysis, reflecting the molecular mechanism underlying the cleavage process. Exoribonucleases 
belong to the two-metal-ion dependent nucleases and this catalysis mechanism is the most 
abundant (Chang et al., 2011a; Yang, 2011).  
 
2.1 5’  3’ Exoribonucleases 
The family of 5’  3’ Exoribonucleases (XRN) are made up of XRN1 (PACMAN in D. melanogaster) 
and its paralog XRN2 (Rat1p in yeast). Both enzymes share a high sequence identity of approx. 40 – 
50% in their N-terminal nuclease region (Chang et al., 2011a; Miki and Großhans, 2013) and act on 
various RNA substrates such as mRNA for XRN1 and miRNA and rRNA for XRN2 (see details below). 
Eukaryotes have usually both XRN1 and -2, which predominantly locate to the cytoplasm and 
nucleus, respectively (Heyer et al., 1995; Johnson, 1997). As plants lack an XRN1 ortholog, the XRN2 
homolog XRN4 takes over its function as it is localized in the cytoplasm (Kastenmayer and Green, 
2000). Due to this separation, XRN1 and -2 have access to different RNA substrates, resulting in 
different tasks. In yeast, XRN2 is essential, whereas deletion of XRN1 causes phenotypes such as 
growth reduction (Amberg et al., 1992; Larimer and Stevens, 1990). In contrast loss of XRN1 causes 
defects in ventral closing and thorax formation in D. melanogaster (Grima et al., 2008) and absence 
of XRN2 leads to phenotypes such as growth delay, sterility and larval molting defects in C. elegans 
(Chatterjee and Grosshans, 2009; Frand et al., 2005; Miki et al., 2014a). 
XRN’s molecular organization is divided into an N-terminal nuclease segment comprising two 
conserved regions CR1 and CR2 connected by an unconserved unstructured part and a C-terminal 
segment. Whereas in XRN1 this C-terminal segment comprises additional well conserved domains 
connected to an unstructured and poorly conserved C-terminal tail, XRN2 lacks these additional C-
terminal domains (Chang et al., 2011b; Jinek et al., 2011; Xiang et al., 2009). XRNs belong to 5’- 
phosphomonoesters producing hydrolases (EC 3.1.13) and use two divalent cations such as Mg2+ or 
Mn2+ for catalysis (Jinek et al., 2011; Kenna et al., 1993; Stevens and Poole, 1995; Xiang et al., 2009). By 
this, XRNs have distant relations with other Mg2+- dependent nucleases such as flap-endonuclease 
FEN-1 and bacteriophage T4 RNase H (Jinek et al., 2011; Yang, 2011). Despite similarities with 
endoribonucleases, XRNs exclusively bind to 5’- monophosphorylated single stranded nucleic acids, 
with high preference for RNA and an approx. 10-fold reduced affinity for DNA (Kenna et al., 1993; 
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Poole and Stevens, 1995; Stevens and Poole, 1995). Recently, the structure of XRN1 in complex with 
a trinucleotide substrate was solved and explains the molecular mechanism of substrate binding. 
Steric hindrance in front of the nuclease cleft formed by helix α1 and a conserved loop (~ residues 
Leu515 – Asp550) prevents double stranded substrate access. Efficient substrate binding is achieved 
by a minimum of three unpaired nucleotides which are bound by XRN through a π – π base stacking 
with His41 and Trp540 in XRN1. Moreover the basic pocket is made up by highly conserved Lys93, 
Gln97, Arg100 and Arg101 residues and the latter two form hydrogen bonds with the 5’ phosphate 
bound oxygens (Jinek et al., 2011). This explains XRN’s preference for 5’ phosphorylated RNAs and 
excludes larger 5’ terminal groups due to electrostatic and sterical limitations. XRNs degrade their 
substrate in a processive manner, by binding an RNA polymer, fully degrading it to mononucleotides 
without release of intermediate products (Jinek et al., 2011; Kenna et al., 1993; Stevens and Poole, 
1995; Xiang et al., 2009). Two metal ion dependent nucleases usually employ two Mg2+ ions, 
coordinated by 8 highly conserved acidic residues, which coordinate the scissile phosphate (3’ 
phosphate) of the RNA phosphate backbone and drive the hydrolytic reaction, which is based on a 
nucleophile substitution Sn2 mechanism. One Mg2+ ion supports the formation of a nucleophile, a 
hydroxide ion, followed by the in-line nucleophilic attack and the second Mg2+ stabilizes the 
pentacovalent phosphate intermediate, which then creates the single 3’ OH nucleotide leaving 
group (Steitz and Steitz, 1993; Yang et al., 2006). For XRNs,  direct coordination of the scissile 
phosphate by the second Mg2+ would be too large for inner-sphere coordination with phosphate-
bound oxygens and are likely to interact through inner-sphere coordinated H2O molecules with the 
scissile phosphate (Jinek et al., 2011). Thus, Jinek et al. hypothesizes a distinct catalytic mechanism 
for XRN1 compared to the canonical two-metal-ion catalysis. The processivity of XRN1 is mainly 
achieved by base stacking residue His41 and 5’- phosphate coordinating Lys93 as mutants thereof 
show substrate intermediates upon catalysis. Therefore Jinek and colleagues propose a Brownian 
ratchet-like mechanism by which the substrate translocation is mediated by His41 π – π base 
stacking in concert with the conserved basic pocket (Jinek et al., 2011). In vitro both XRNs show little 
substrate specificity, but execute specialized functions in vivo, pointing to an underlying regulatory 
network for these enzymes.  
 
2.1.1 The 5’  3’ Exoribonuclease 2 is a Complex and Acts on Multiple Substrates 
Initially, XRN2 was found to be involved in rRNA maturation, but soon more substrates sensitive to 
XRN2 were identified (Miki and Großhans, 2013; Nagarajan et al., 2013). Among them are functional 
RNAs from transcription and translation, such as pre-mRNA and tRNA, respectively as well as small 
RNAs involved in gene silencing. Moreover functions such as transcription termination and miRNA 
release off AGO were discovered, which emphasizes its multifunctional character.  
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As described above, there are many RNA species involved in transcription and translation. 
Accordingly, XRN2 contributes significantly to their maturation and quality control. A precursor-rRNA 
(pre-rRNA) molecule is divided in the functional 18S, 5.8S and 25S (in yeast; 28S in mammals) rRNA 
fragments, two external transcribed spacers (5’ and 3’ ETS) and two internal transcribed spacers (ITS1 
and – 2) (Figure 3) (Henras et al., 2008). XRN2 is involved in 5’ trimming of 5.8S and 25S/28S as well as 
clearance of some spacer fragments (Amberg et al., 1992; Couvillion et al., 2012; Petfalski et al., 1998; 
Wang and Pestov, 2011; Zakrzewska-Placzek et al., 2010). However prior endonucleolytic cleavage of 
the pre-rRNA is necessary for substrate access. The MRP endonuclease (evolutionary related to 
ribonucleoprotein RNase P) generates an XRN2 competent substrate by cleavage within the ITS1 
upstream of the 5.8S, which is subsequently trimmed by XRN2 (Shadel et al., 2000). Similarly, XRN2 
trims the 5’ extension of a 25S rRNA precursor after endonucleolytic cleavage at ITS2 (Henry et al., 
1994; Schmitt and Clayton, 1993). Recruitment of XRN2 to the pre-rRNA is mediated by NOP4 and 
NOP15 in yeast, as their potential RNA remodeling activity allows for XRN2 substrate access 
(Granneman et al., 2011). However, 5’-end trimming is not exclusively maintained by XRN2 as 
recently identified Rrp17 exonuclease redundantly acts on 5’-end rRNA maturation (Oeffinger et al., 
2009). Moreover XRN1 can substitute for XRN2 function in rRNA maturation, in case of loss or 
inactivity (Fang et al., 2005; Henry et al., 1994). Most work elucidating rRNA maturation was done in 
yeast, but this process seems to be conserved in mammals as XRN2 RNAi in mouse LAP3 cells result 
in similar accumulation of extended 5.8S and 28S rRNAs (Wang and Pestov, 2011). Due to XRN2’s 
processive activity, questions about termination of this trimming process remain. Apart from rRNA 
maturation, XRN2 is indicated to support the exosome in clearance of aberrant pre-rRNA species 
(Fang et al., 2005; Wang and Pestov, 2011). Furthermore XRN2 mediates small nucleolar RNA 
(snoRNA) maturation in a similar fashion to rRNA maturation, where endoribonuclease Rnt1 renders 
suitable RNA substrates for 5’ trimming of snR190, U14 and snR72-78 (Chanfreau et al., 1998; Petfalski 
et al., 1998; Qu et al., 1999). These small ncRNAs bind to pre-rRNAs and support the processing 
thereof. On the other hand, maturation of tRNAs is driven by RNases, such as RNase Z and RNase P, 
processing the 3’- and 5’-end, respectively (see above) (Minagawa et al., 2004; Xiao et al., 2001). 
However, defective tRNAs are rapidly cleared by XRN1 and XRN2, to avoid production of deleterious 
proteins (Chernyakov et al., 2008). Similarly, XRN2 is involved in surveillance of pre-mRNA. The tight 
regulation of mRNA quantities correlate with protein production, hence XRN2 and the exosome 
compete with the splicing machinery for pre-mRNAs as a substrate (Bousquet-Antonelli et al., 2000; 
Brannan et al., 2012; Das et al., 2003). As defects within pre-mRNAs would lead to erroneous protein 
products, quality control of aberrant pre-mRNAs and subsequent decay by the exosome and XRN2 
are necessary. This task is predominantly executed by the exosome in yeast, but in human cells XRN2 
plays a more important role (Davidson et al., 2012; Gudipati et al., 2012). 
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 Figure 3: The scheme illustrates the rRNA maturation and RNases involved in this process (adapted from 
Granneman et al., 2011). 
 
Whereas maturation and decay of RNAs are important for their function and homeostasis/quality 
control, degradation of RNAs can also influence cell aging and senescence as it was discovered for 
the TERRA RNA and XRN2. Telomeres are repeat sequences at the end of chromosomes, which are 
shortened each DNA replication and telomere loss can lead to stop in growth, senescence or 
apoptosis. Hence the telomerase replenishes and maintains the integrity of telomeres, but it is 
suggested that its activity is repressed by telomeric repeat-containing RNA (TERRA) (O’Sullivan and 
Karlseder, 2010). These TERRA molecules bind telomere sequences and XRN2 is implicated in their 
degradation and thus indirectly regulates telomerase activity (Luke et al., 2008). Likewise, XRN2 
catalysis is thought to induce transcription termination. For RNAP II transcription (see details above) 
to be terminated, there is increasing evidence for XRN2 to play a major role, which is explained by 
the torpedo model (Kim et al., 2004; West et al., 2004). After cleavage of the nascent pre-mRNA 
transcript, RNAP II remains bound to the DNA strand and continues transcription. Indeed, the 
cleavage event yields a 5’ monophosphate and serves as an entry point for XRN2. Thus XRN2 starts 
degradation and, by colliding, displaces RNAP II from the DNA strand to terminate transcription. 
However reports in yeast show this mechanism not to be essential and in mammals only a subset of 
genes are sensitive to XRN2 mediated transcription termination (Banerjee et al., 2009; Brannan et al., 
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2012; Luo et al., 2006). Thus, the torpedo model explains a specialized process rather than a general 
mechanism. Of note, XRN2 is also implicated in premature termination of RNAP II transcription as 
well as termination of RNAP I pre-rRNA- and intergenic RNAP II pri-miRNA transcription (Ballarino et 
al., 2009; El Hage et al., 2008; Kawauchi et al., 2008). Taken together XRN2 mediated decay involves 
maturation and quality control of functional RNAs as well as contributes to processes like cell aging 
and transcription termination. 
 
So far, all described functions of XRN2 are related to RNA decay, however a recent function with no 
obvious connection to catalysis was discovered. It was shown that XRN2 depleted worm lysates 
incubated with immunoprecipitated miRNA-AGO complexes showed elevated miRNA levels 
remaining on AGO (Chatterjee and Grosshans, 2009). Thus XRN2 depletion leads to reduced release 
activity, however the underlying mechanism remains elusive.  
Small RNAs, such as miRNAs, gained much attention in the last decade and efforts tried to identify 
specific RNases responsible for their decay. In C. elegans, XRN2 has been found to degrade miRNAs, 
as knock-down of XRN2 rescued let-7 point mutant worms by increasing let-7 levels (Chatterjee and 
Grosshans, 2009). However, further analysis revealed that only a subset of miRNAs are sensitive to 
XRN2 degradation, indicating a targeted process for miRNA degradation in vivo (Miki et al., 2014a). In 
contrast, miRNAs might simply be cleared by multiple RNases, depending on their cellular location 
and accessibility. In a less well-understood mechanism, exogenous non-targeting siRNAs are cleared 
by XRN2 (Wei et al., 2011). These small RNAs induce NPGPx (non-selenocysteine-containing 
phospholipid hydroxyperoxide glutathione peroxidase) expression, followed by complex formation 
through covalent binding of NPGPx to XRN2 and small RNA degradation. Whether this process is 
relevant under physiological conditions remains unclear. 
As just described, XRN2 has many different substrates as well as specific functions, but one wonders 
how this is achieved by a single molecule? Indeed, during purification of yeast XRN2, a second 
protein called Rat1p interacting protein (Rai1p) was readily co-purified (Stevens and Poole, 1995; 
Xiang et al., 2009). Analysis showed, that binding of Rai1p confers stability to XRN2 and 
enhances/activates nuclease activity (Xiang et al., 2009; Xue et al., 2000). Moreover Rai1p itself was 
found to harbor pyrophosphatase activity (Xiang et al., 2009). Interestingly, complex formation of 
XRN2 with Rai1p permits the enzyme complex to access a much broader spectrum of substrate, as 
XRN2 alone is limited to 5’ monophosphorylated RNA substrates. However, Rai1p homologs 
Dom3Z/DXO seem not to bind XRN2 (Xiang et al., 2009). Interestingly, we recently identified C. 
elegans XRN2 to form a complex with PAXT-1, but no homology of PAXT-1 and Rai1p is detected (Miki 
et al., 2014b). Instead PAXT-1 seems to bind XRN2 through its N-terminal segment containing a 
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domain of unknown functions (DUF3469) also termed XRN2 binding domain (XTBD), which is not 
detected in Rai1p nor in any other yeast protein (Miki et al., 2014b). Loss of PAXT-1 results in reduced 
XRN2 protein levels, whereas mRNA levels remain unaffected, suggesting a stabilizing effect of PAXT-
1 on XRN2 (Miki et al., 2014b). Other XRN2 interactions with XTBD-containing proteins were 
identified in Tetrahymena thermophila and humans (Brannan et al., 2012; Couvillion et al., 2012; Miki 
et al., 2014b). T. thermophila XRN2 associates in a ternary complex with Ago/Piwi protein Twi12 and 
XTBD-containing protein Tan1, with both binding to independent XRN2 interfaces. Whereas Twi12 
seems to stabilize XRN2, no function is attributed to Tan1 (Couvillion et al., 2012). How these findings 
relate to reports from C. elegans, where XTBD- containing protein PAXT-1 confers stability, remain 
elusive. Co-immunoprecipitation experiments in humans identified two XTBD- containing proteins 
NKRF and CDKN2AIP/CARF to interact with XRN2 and Pfam alignments of DUF3469 (XTBD) suggests 
a third XTBD-containing protein CDKN2AIPNL to exist in an XRN2 complex (Brannan et al., 2012; 
Close et al., 2012; Miki et al., 2014b). Whereas NF-κ-B-repressing factor (NKRF) acts as a transcriptional 
repressor, collaborator of ARF (CARF/CDKN2AIP) is a tumor suppressor that acts through p53-
activation, but CDKN2AIPNL has no attributed functions (Cheung et al., 2014; Feng et al., 2002; Hasan 
et al., 2002, 2004). Until now, direct interaction was only shown for the C. elegans PAXT-1 – XRN2 
complex, but there is evidence for other XTBD-containing proteins to form similar complexes with 
their XTBD domain (Miki et al., 2014b). Accordingly, XRN2 may exists in multiple complexes that 
potentially affect or regulate its function. Moreover, studies on transcription termination identified 
higher order complexes of XRN2. In yeast, a trimeric complex consisting of Rat1p, Rai1p and Rtt103 
was identified, which localizes to the 3’ end of protein coding genes (Kim et al., 2004). Interestingly, 
Rtt103 binds to phosphorylated serine2 of the CTD of RNAPII and possibly links the exonuclease 
complex to the transcription machinery (Kim et al., 2004). In vitro analysis show however, that a this 
trimeric complex is not enough for transcription termination (Dengl and Cramer, 2009). Similarly, 
human XRN2 is recruited to RNAPII by the protein complex p54nrb/PSF, which was found to stably 
interact with the C-terminus of XRN2. p54nrb/PSF itself is a multifunctional protein complex and 
involved in transcription, splicing and polyadenylation of nascent mRNA transcripts (Gozani et al., 
1994; Liang and Lutz, 2006). It is thus suggested, that p54nrb/PSF couples pre-mRNA 3’-end 
processing and transcription termination (Kaneko et al., 2007).  
 
2.1.2 5’  3’ Exoribonuclease 1 
XRN1 is the cytoplasmic paralog of XRN2 and shares high sequence identity with XRN2 in its N-
terminal segment (see above). However XRN1 acquired a set of domains absent from XRN2, which 
possibly provides additional functions to the enzyme (Chang et al., 2011b; Jinek et al., 2011). Both, 
the SH3- and PAZ/Tudor domain mediate structural stability to XRN1, by interaction with the 
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nuclease region (Jinek et al., 2011). Whereas the SH3-domain achieves this through non-canonical 
binding due to the lack of canonical residues involved in proline-rich peptide interactions, Jinek et 
al. (2011) hypothesize the PAZ/Tudor domain to substitute for Rai1p induced stabilization because 
of the vast interface formed by this interaction (Jinek et al., 2011). The canonical PAZ and Tudor 
domains bind RNAs and motifs containing methylated arginine, respectively. In XRN1, however the 
functional surfaces of the PAZ/Tudor domain are covered by an SH3 protruding loop and thus 
exclude additional binding capabilities by these domains (Jinek et al., 2011). For the winged-helix 
domain, which is located above the catalytic center, it is postulated that it supports RNA binding and 
potential catalytic activity and that it may act as a scaffold for possible protein-protein interaction 
(Jinek et al., 2011). 
XRN1 mainly localizes throughout the cytoplasm, but is sometimes found in distinct foci called P-
bodies, co-localizing with enzymes such as decapping factor DCP2 and LSM1-7 complex supporting 
degradation by coupling deadenylation and decapping events (Bashkirov et al., 1997; Cougot et al., 
2004; Heyer et al., 1995; Johnson, 1997; Newbury, 2006). P-bodies are however thought to be storage 
sites for inactive mRNAs, as mRNAs can either be degraded by XRN1 or released to continue 
translation (Brengues et al., 2005; Eulalio et al., 2007; Stalder and Mühlemann, 2009). Yet, these foci 
are no prerequisite for mRNA degradation, but seem to be increased during stress response (Cougot 
et al., 2004; Kedersha et al., 2005; Sheth and Parker, 2003).  
The main task of XRN1 is the clearance of mRNA species. Access to this substrate, however needs 
preceding mRNA processing to render unpaired 5’ monophosphorylated nucleotides. One way is 
removal of the 5’ end of the mRNA through decapping enzymes such as DCP2 and its activator DCP1, 
which usually occurs after deadenylation of the mRNA, however deadenylation is not a prerequisite 
(Braun et al., 2012; Gazzani et al., 2004; Lejeune et al., 2003; Muhlrad et al., 1994). As previously 
discussed, endonucleolytic cleavage of mRNAs by siRNA loaded Argonaute also results in XRN1 
competent mRNA substrate (Chekulaeva et al., 2011; Sheth and Parker, 2003). Moreover quality 
control of mRNAs through nonsense-mediated decay (NMD) protects the organism from harmful 
aberrant mRNAs and triggers XRN1 mediated clearance of these mRNAs (reviewed in Rebbapragada 
and Lykke-Andersen, 2009). When a premature termination codon (PTC) is detected, NMD triggers 
its endonucleolytic cleavage through SMG6 endonuclease (which belongs to the FEN1 ribonuclease 
superfamily) or direct induction of exonucleolytic decay from both ends (Eberle et al., 2009; Glavan 
et al., 2006; Huntzinger et al., 2008; Yang, 2011). In addition, the exosome, a multi-subunit protein 
complex with 3’  5’ exoribonuclease activity, cooperatively and/or independently degrades 
deadenylated and endonucleotlytically cleaved mRNAs (see below). Noteworthy, neither XRN1 nor 
the exosome can substitute for each other in multicellular organisms, suggesting that at least a 
subset of transcripts are individually regulated and controlled by either enzyme (Jones et al., 2012; 
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Newbury and Woollard, 2004). Besides its predominant role in mRNA degradation, XRN1 has also 
been implicated in degradation of some miRNAs, however this evidence seems to support a model, 
where XRN1 simply clears unprotected miRNAs rather than acting as a specific miRNase (Bail et al., 
2010; Chatterjee et al., 2011).  
Despite its important role in mRNA surveillance and decay, XRN1 is not essential in unicellular 
eukaryotes, as its knock-out causes phenotypes such as reduction in growth rate, decreased rates of 
diploid formation and sporulation, defects in meiotic recombination and reduced transcription of a 
subset of genes due to XUT (XRN1-sensitive unstable transcripts) accumulation (Amberg et al., 1992; 
van Dijk et al., 2011; Larimer and Stevens, 1990; Tishkoff et al., 1995). In contrast multicellular 
organisms depend on XRN1 as null mutations in D. melanogaster are lethal and XRN1 mutations 
cause specific developmental phenotypes, such as reduced fertility and failure in epithelial sheet 
sealing (Grima et al., 2008; Zabolotskaya et al., 2008). Similar observations were made in C. elegans, 
by XRN1 RNAi, however no XRN1 mutant worm line exist to verify these observations (Newbury and 
Woollard, 2004). This suggests, that XRN1 is specifically deployed for degradation of certain 
transcripts involved in development. In line with these observations, studies of patient derived cell 
samples link XRN1 with osteosarcoma, a common childhood cancer (Zhang et al., 2002). This type of 
cancer originates from mesenchymal cells, that failed to properly differentiate and XRN1 mRNA levels 
were reduced, probably due to a mis-sense mutation within the XRN1 gene.  
Whereas subunits of XRN2 complexes form strong interactions and mainly act as stabilizers, XRN1 
has not been found to exist in such prominent and stable complexes. However XRN1 interacts with 
proteins such as DCP1, LSM1-7, PAT1 and UPF1, UPF2, UPF3X implicated in mRNA decapping and 
NMD, respectively (Bouveret et al., 2000; Lejeune et al., 2003; Nissan et al., 2010). Interestingly, in C. 
elegans and yeast, XRN1 was found to interact with DCS1, a scavenger decapping enzyme and DCS1 
stimulated XRN1 activity independently of its own catalytic activity in vitro and in vivo (Bossé et al., 
2013; Sinturel et al., 2012). 
 
2.2 The Exosome – Example of a 3’  5’ Exoribonuclease 
The eukaryotic exosome is a multi-subunit RNase complex engaged in many RNA decay-, quality 
control- and processing pathways (see above) and is conserved throughout all kingdoms of life. 
Whereas ancestral exosomal complexes rely on phosphorolytic catalysis with their 6 RNase PH 
domains, the eukaryotic exosome switched to a hydrolysis mechanism. Its additional nuclease 
subunits Rrp44 and Rrp6 supply catalytic activity, whereas all RNase PH domains are catalytically 
inactive and seem to act solely as scaffolds (Januszyk and Lima, 2014; Schneider and Tollervey, 2013).  
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 The molecular structure of the exosome core (EXO9) is made up of 9 subunits that forms a barrel-
like structure, sharing similarities to the proteasome or the bacterial polynucleotide phosphorylase 
(PNPase) (Liu et al., 2006). In eukaryotes, the barrel is formed by six subunits 
(Rrp41/42/43/45/46/Mtr3) harboring a phosphorolytic 3’  5’ exoribonuclease domain homologous 
to RNase PH 1 or - 2, which are however catalytically inactive (Liu et al., 2006). Rrp40, Rrp4 and Csl4 
subunits form a cap on top of the barrel and contain S1 and/or KH RNA-binding domains. The EXO9 
barrel forms a channel with a 8 to 10 Å opening, capable of accommodating only single stranded 
RNA (Liu et al., 2006). With the lack of active RNase PH domains, the exosome acquired two catalytic 
competent subunits, Rrp6 and Rrp44, to form the canonical EXO11 complex. Structural analysis 
revealed Rrp44/Dis3 (human) to bind on the base of the barrel and to contain a processive 3’  5’ 
exoribonuclease domain homologous to RNase II/R as well as an endoribonucleolytic PIN (PilT N 
terminus) domain (Bonneau et al., 2009; Frazão et al., 2006; Lorentzen et al., 2008). The PIN domain, 
which is homologous to T4 RNase H, however shows activity only at unphysiological high 
manganese concentrations of 5 mM (Lebreton et al., 2008). Furthermore Rrp44’s catalytic activity 
depends on the integrity of the EXO9 channel, as the RNA substrate needs to be threaded through 
the channel to reach the nuclease cleft (Dra̧zkowska et al., 2013; Wasmuth and Lima, 2012). For 
substrate longer than 35 nt, this seems a prerequisite but if shorter substrates have alternative access 
paths to Rrp44 remains unclear (Dra̧zkowska et al., 2013; Wasmuth and Lima, 2012). Interestingly, 
humans have three Rrp44 homologs (DIS3, DIS3L, DIS3L2), which are tied to different subcellular 
compartments and exosome complexes are found in the cytoplasm and the nucleus associated with 
DIS3L and DIS3, respectively (Malecki et al., 2013; Tomecki et al., 2010). No interaction of the exosome 
with DIS3L2 has been described yet. In contrast to Rrp44, Rrp6 locates to the top of the exosome by 
forming a vast binding interface with EXO9 components and supplies distributive 3’  5’ 
exonucleolytic activity to the exosome (Januszyk et al., 2011; Midtgaard et al., 2006). The catalytic 
domain is homologous to RNase D, dependent on two Mg2+ ions, and substrate pools of Rrp6 and 
Rrp44 are non-redundant (Gudipati et al., 2012; Kiss and Andrulis, 2010). It has been shown that Rrp6 
lacking yeast accumulate nuclear RNA species such as pre-rRNA and snRNA, indicating a specific role 
for an Rrp6-loaded exosome in nuclear RNA processing (Allmang et al., 1999, 2000; Neil et al., 2009).  
Moreover, specialized complex configuration exist to serve its compartmentalization as well as 
regulation, with a cytoplasmic EXO10 exosome (EXO9 – Rrp44), a nuclear EXO11 and an EXO9 – Rrp6 
complex, suggested to exist in the nucleolus (Januszyk and Lima, 2014). 
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II Results 
During the last decade, microRNAs (miRNA) emerged as important regulator of post-
transcriptional gene expression, controlling development, cell growth and homeostasis. Accordingly 
miRNAs are implicated in diseases such as cancer, and they are deregulated in many tumors. Hence 
dissecting the molecular basis of miRNA biogenesis, mRNA silencing and the active turnover of 
miRNA marks an important research goal. Previously, we identified the 5’  3’ exoribonuclease XRN2 
as a miRNA nuclease in C. elegans. Moreover, we recently identified PAXT-1 as a subunit of an XRN2 
complex, which seems to stabilize XRN2. To dissect its function I was expressing XRN2 and PAXT-1 – 
XRN2 complexes recombinantly to perform in vitro turnover assays, interaction studies and stability 
assays. Furthermore, I crystallized the XTBD – XRN2 complex and together with Dr. Heinz Gut solved 
its structure. Dr. Iskra Katic and I then confirmed in vitro results concerning the importance of Tyr56 
in vivo by using MosSCI and CRISPR technology to generate mutant worms.  
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Abstract 
The ribonuclease XRN2 is an essential player in RNA metabolism. In Caenorhabditis elegans, XRN2 
functions in a complex with PAXT-1, which shares a putative XRN2-binding domain (XTBD) with 
otherwise unrelated mammalian proteins. Here, we characterize structure and function of XTBD in 
complex with XRN2. Although XTBD stably interconnects two XRN2 domains through numerous 
interacting residues, we identify a critical residue whose mutation suffices to disrupt XTBD – XRN2 
complexes in vitro, and recapitulate paxt-1 null mutant phenotypes in vivo. XRN2-binding is highly 
conserved as vertebrate XTBD-containing proteins form complexes with XRN2 in vitro, and human 
CDKN2AIPNL/C2AIL can substitute for PAXT-1 in vivo. With three distinct XTBD-containing proteins 
existing in vertebrates, stable binding suggests that cellular XRN2 partitions to distinct heterodimeric 
complexes, likely differing in subcellular localization or function. In C. elegans, complex formation with 
the unique PAXT-1 may serve to preserve the stability of XRN2 when not bound to substrate.  
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Introduction 
Ribonucleases (RNases) are central to both RNA processing and degradation events and hence key 
enzymes in RNA metabolism. Thus, the nuclear 5’  3’ exoribonuclease XRN2 functions in ribosomal 
and small RNA processing (Chanfreau et al., 1998; Couvillion et al., 2012; Geerlings et al., 2000; 
Petfalski et al., 1998; Wang and Pestov, 2011; Zakrzewska-Placzek et al., 2010), transcriptional 
termination (Kim et al., 2004; West et al., 2004), clearance of aberrant pre-mRNA (Davidson et al., 
2012) and hypomodified tRNA (Chernyakov et al., 2008), degradation of miRNAs (Chatterjee and 
Grosshans, 2009) and other pathways (reviewed in Miki and Großhans, 2013; Nagarajan et al., 2013). 
Accordingly, XRN2 is conserved from yeast to humans, and encoded by an essential gene in both yeast 
and worms (Amberg et al., 1992; Miki et al., 2014a). A cytoplasmic paralogue of XRN2, XRN1, plays a 
central role in mRNA degradation (Parker and Sheth, 2007). The two enzymes share a substrate 
preference for 5’ monophosphorylated, single-stranded RNAs (Jinek et al., 2011; Kenna et al., 1993; 
Poole and Stevens, 1995; Stevens and Poole, 1995). 
In yeast, the XRN2 protein Rat1p occurs in a complex with Rai1p (Rat1 interacting protein; Stevens and 
Poole, 1995; Xiang et al., 2009), a protein that promotes XRN2 activity through mechanisms that 
remain to be identified (Xiang et al., 2009; Xue et al., 2000). However, the metazoan Rai1p orthologues 
Dom3z/DXO do not bind to their respective XRN2s (Xiang et al., 2009). In C. elegans, XRN2 forms 
instead a complex with the novel protein PAXT-1 (Partner of XRN-Two) (Miki et al., 2014b). Loss of 
PAXT-1 causes a reduction in XRN2 levels, and, when worms are grown at a relatively high temperature 
of 26°C, embryonic lethality, which can be prevented by increased XRN2 gene levels (Miki et al., 
2014b). As paxt-1 mutations cause reduced XRN2 protein but not mRNA levels, PAXT-1 may stabilize 
the XRN2 protein (Miki et al., 2014b). 
Although PAXT-1 is 375 amino acids (aa) long, its N-terminal 121 amino acids suffice to co-
immunoprecipitate XRN2 and restore animal viability and XRN2 levels when expressed as a transgene 
in paxt-1 mutant animals (Miki et al., 2014b). This portion of PAXT-1 also comprises a predicted domain 
of unknown function, DUF3469, and although PAXT-1 is not well conserved outside nematodes, this 
domain is also found in unrelated vertebrate and ciliate but not yeast proteins (Miki et al., 2014b). 
Although it is not known whether these proteins also bind XRN2, three of them, mammalian NKRF/NRF 
and CDKN2AIP/CARF, and ciliate Tan1 were observed in XRN2 complexes  (Brannan et al., 2012; Close 
et al., 2012; Miki et al., 2014b; Couvillion et al., 2012). Hence, DUF3469 may mediate XRN2 binding 
(Miki et al., 2014b).   
Here, we have used biochemical, crystallographic and molecular genetic approaches to test whether 
DUF3469 is an XRN2-binding domain (XTBD), dissect its structure, and elucidate its function.  We 
identify a core XTBD domain and present its crystal structure in complex with XRN2. We uncover a 
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conserved interaction interface, on which a single amino acid on XTBD makes crucial contributions to 
complex formation, such that its mutation disrupts the complex in vitro and in vivo and renders mutant 
animals inviable. We demonstrate that XTBDs are generic XRN2 binders, across species, in vitro, and 
that, despite limited sequence similarity, human CDKN2AIPNL/C2AIL can substitute for C. elegans 
PAXT-1 in vivo. Although XRN2 has low thermal stability, which PAXT-1 binding greatly increases, it 
retains activity at elevated temperature in vitro. This appears to be a consequence of a stabilizing effect 
of substrate binding, in turn suggesting that a function of PAXT-1 is to preserve stability of 'empty' 
XRN2 to buffer cellular RNase activity. 
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Results 
 
The Crystal Structure of the XTBD – XRN2 Complex Reveals a Conserved Binding Interface 
Our previous work examined the function of the N-terminal amino acids 1 - 121 of C. elegans PAXT-1, 
which contains the DUF3469 domain, and showed that this truncated PAXT-1 sufficed for both binding 
to XRN2 in vivo and restoration of viability in paxt-1(0) worms (Miki et al., 2014b). However, Pfam 
annotates the boundaries of this domain as residues 7 – 93 (http://pfam.xfam.org/family/DUF3469). 
Hence, we sought to redefine the XTBD core element. Based on HHPred secondary structure 
predictions (Söding et al., 2005) and disorder analysis by PSIPRED Protein Analysis Workbench (Buchan 
et al., 2013) and DisEMBL (Linding et al., 2003), we decided to test recombinant proteins comprising 
residues 1 – 121, 1 – 96,  and 1 – 75, respectively, for binding to XRN2. We found that the binding 
properties of all three polypeptides were comparable to that of the full-length protein (Fig. S1A). Thus, 
at 75 amino acids the functional XTBD is substantially smaller than previously annotated. 
To obtain structural information on XTBD, we sought to express and purify an XRN2 – PAXT-1_1-75 
complex for crystallographic analysis. Extensive protein engineering on XRN2 was necessary to yield 
high-quality diffracting protein crystals. We deleted a zinc-finger containing loop (residues 258 – 294), 
a predicted disordered region in the middle of the protein (residues 417 – 532), and the glycine-rich C-
terminus (residues 788 – 975). This protein construct is referred to as XRN2ΔZLC. Following co-
expression of XRN2ΔZLC and PAXT-1_1-75 in bacterial cells, purification and crystallization, we 
determined the crystal structure of the 83 kDa complex at 2.85 Å resolution. The macromolecular 
complex crystallized in space group P212121 with six XTBD – XRN2ΔZLC heterodimers in the 
crystallographic asymmetric unit and a solvent content of ~64%. The structure was determined by 
molecular replacement and model building was carried out with the help of phased anomalous 
difference Fourier electron density maps obtained from seleno-methionine derivative crystals. Data 
collection and refinement statistics are summarized in Table 1. The final XTBD – XRN2ΔZLC structure 
consists of residues 4 – 25, 35 – 149, 153 – 413, and 534 – 787 for XRN2ΔZLC (chain A) and 1 – 73 for 
XTBD (chain B), which show clear electron density.  
A previous domain assignment of XRN2 was based on sequence conservation and annotated two 
domains, CR1 (conserved region 1; corresponding to residues 1 – 409) and CR2 (residues 543 – 713), 
connected by an non-conserved disordered region and a poorly conserved C-terminus (Xiang et al., 
2009). Based on our structural data, and taking into account previous structures of Rat1p (Xiang et al., 
2009) and XRN1 (Jinek et al., 2011), we further refine the XRN2 domain classification.  We now define 
the nuclease core domain 1 (NCD1, residues 1 – 310), the nuclease core domain 2 (NCD2, 311 – 612), 
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the PAXT-1 binding domain (PBD, 613 – 705), the C-terminal domain 1 (CTD1, 706 – 787) and the C-
terminal domain 2 (CTD2, 788 – 975) (Fig. 1A and 1B). The structure of XRN2ΔZLC is highly similar to S. 
pombe Rat1 (PDB 3FQD) (Xiang et al., 2009) with a root-mean-square deviation (r.m.s.d.) of 1.46 Å over 
580 aligned Cα atoms (53% sequence identity). It also superimposes very well onto the exonuclease 
cores of D. melanogaster and K. lactis XRN1s with r.m.s.d. values of 1.51 Å (503 aligned Cα atoms, 44% 
sequence identity, PDB 2Y35) (Jinek et al., 2011) and 1.36 Å (475 atoms, 42% identity, PDB 3PIE) (Chang 
et al., 2011), respectively.  
Consistent with the PAXT-1 truncation analysis above, the crystal structure confirms PAXT-1_1-75 as 
the core XRN2-binding domain. It binds to a large groove on XRN2, which is formed by NCD1 and PBD. 
XRN2 residues 645 – 681 form a long loop protruding from the globular core of the PBD and fold around 
the base of a large α-helix, known as the tower domain (residues 108-139; Xiang et al., 2009) (Fig. 1B 
and S1B). XTBD folds into a globular four-helix bundle (H1 – H4) connected by three loops (L1 – L3) 
(Figure 1C). H1 – H3 form an antiparallel helical array and H4 folds back on top of H2/H3 at a 90° angle. 
H1 is short, comprising only six residues, whereas helices H2 – H4 are much longer (10-15 residues). 
The four-helical bundle is mainly stabilized by hydrophobic helix – helix interactions together with 
additional polar interactions between side chains located on neighboring helices. A peculiarity is L3, 
connecting H3 and H4, which is in a completely linear conformation (Fig. S1C). Although a DALI (Holm 
and Rosenström, 2010) search against the Protein Data Bank (PDB) identified many structures with a 
topologically similar arrangement of three to four α- helices, either as single units or as part of a larger 
helical array, these differed substantially in their helix to helix angles and therefore represent only 
distant hits with low Z-scores (Z < 4.5) and rather large r.m.s.d. values (> 3.0 Å). Hence, it seems that 
the four-helical bundle of XTBD represents a structurally unique arrangement for XRN2 binding with 
no closely related protein structure present in the PDB. 
 
XTBD Tyrosine 56 is Critical for Complex Formation in vitro and in vivo 
Crystal packing analysis suggests that the XTBD – XRN2ΔZLC complex exists as a single heterodimer and 
SEC MALS (size exclusion coupled to multi-angle light scattering) experiments confirm this. The XTBD 
– XRN2ΔZLC complex elutes as monodisperse heterodimer with a measured mass of 80.9 kDa 
(calculated mass: 83.0 kDa) (Fig. S2A). Analysis of the protein – protein interface by PISA (Krissinel and 
Henrick, 2007) and EPPIC (Duarte et al., 2012) reveals a rather small buried solvent-accessible area on 
either protein of ~1000 Å2 upon complex formation. 24 residues of XTBD interact with 36 residues of 
XRN2ΔZLC in a hydrophobic and polar manner, and these interface residues are highly conserved as 
shown by ConSurf analysis of both proteins (Ashkenazy et al., 2010; Celniker et al., 2013) (Fig. 2A). The 
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hydrophobic character of the interface is mainly formed by XTBD residues on L1, H3, and L3 (Trp14, 
Ile37, Cys41, Leu52, Cys54, Tyr56, Leu60) and contributes to interaction with XRN2ΔZLC residues Val553, 
Phe560, Pro591, Pro650, Ile652, Asp653, Pro656, Pro677, and Phe678 (Fig. 2B and S2B). Additional 
binding energy is provided by the formation of 13 hydrogen bonds and three salt bridges upon complex 
formation (Fig. 2C, 2D and S2C). Although the XTBD - XRN2 interface is relatively small at ~1000 Å2, the 
complex is very stable and resists disruption by high salt washes (data not shown) and high dilution 
(Fig. S2A).  
To further dissect the XTBD – XRN2ΔZLC interaction, we generated PAXT-1 interface point mutant 
proteins based on the structural information. To test their binding capacities we co-expressed them 
with XRN2 and purified the PAXT-1 mutant proteins through their His6-tags by Immobilized Metal 
Affinity Chromatography (IMAC) (Fig. 2E). While XRN2 co-purification through PAXT-1 pull-down was 
unaffected by the PAXT-1 point mutations Trp14-to-Ala and Cys41-to-Gly, respectively, less XRN2 was 
seen with the Cys54-to-Gly mutation. However, this mutation also decreased PAXT-1 levels, leaving it 
unclear whether decreased XRN2 purification truly reflects decreased binding capacity. By contrast, 
the Tyr56-to-Ala mutation completely abrogated interaction of XTBD with XRN2 without destabilizing 
PAXT-1, highlighting Tyr56 as a key interface residue.  
The fact that a single point mutation, Tyr56-to-Ala, abrogates binding although numerous side chains 
contribute to the total binding energy of the interface, appears surprising. However, it is explained by 
its crucial role in shaping the unique linear conformation of the loop L3. With all seven residues, 
XTBD_51-57 engaged in XRN2 binding (Fig. S2C), L3 contributes 33% (338 Å2) buried surface area (BSA) 
and four hydrogen bonds to the XTBD – XRN2 interface, whereas the other 17 interacting residues 
together contribute the remaining 698 Å2 BSA and nine hydrogen bonds. Mutation of Tyr56 to alanine 
lacks the key constraint for the 51 – 57 conformation due to the missing phenol ring, which is normally 
sandwiched between Leu45 (XTBD, H3) and Pro656 (XRN2ΔZLC), forming a CH – π – interaction with 
Pro656 (XRN2ΔZLC) (Fig. 2C). Through its hydroxyl group, Tyr56 also forms hydrogen bonds (2.8 Å) with 
the backbone carbonyl of Asp653 (XRN2ΔZLC) (Fig. 2C). A second constraining residue, XTBD Cys54, is 
found in hydrophobic interaction with Pro656 (XRN2ΔZLC) and additionally forms a hydrogen bond with 
the backbone carbonyl of Leu675 (XRN2ΔZLC) (Fig. S2C). Together, Cys54 and Tyr56 promote formation 
of an isolated β-bridge between backbone atoms of XTBD_Glu55 and XRN2_Asp658 (Fig. 2D). Mutation 
of Tyr56 to alanine and Cys54 to glycine removes the constraining side chains for this stretch and 
induces backbone flexibility, thus compromising/disrupting all interactions between 51 – 57 XTBD 
residues and XRN2. The resulting loss of one third of BSA explains the severe consequences of these 
mutations. By contrast Trp14-to-Ala or Cys41-to-Gly have only limited effects on the BSA and thus no 
major effect on complex formation in vitro.  
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To validate the importance of XTBD Tyr56 for XRN2 binding under physiological conditions, we sought 
to test whether mutating it would similarly translate into a loss of interaction in vivo. We utilized 
genome editing through CRISPR/Cas9 and homology-directed DNA repair (Arribere et al., 2014; 
Dickinson et al., 2013) to create the Tyr56-to-Ala point mutation in endogenous PAXT-1. Strikingly, 
when we grew the resulting paxt-1(xe29) worms at 26°C, they arrested as L1 larvae, just like paxt1(0) 
animals (Fig. 2F). Also, just like in paxt-1(0) animals, (Miki et al., 2014b), accumulation of XRN2 was 
reduced and PAXT-1 not detectable as revealed by western blotting (Fig. 2G). Altogether, our data thus 
identify Tyr56 as a critical residue for interaction with XRN2 in vitro and in vivo, and explain the 
structural basis of this importance, as well as the high degree of conservation of this XTBD residue: In 
XTBDs, this position is always held by residues with aromatic side chains (Tyr, Phe, Trp, Fig. 1A), which 
can occupy the XRN2 Pro656 pocket via a stacking interaction. 
 
XTBD Is a Generic XRN2 Adapter 
Although different XTBD/DUF3469-containing proteins occur in complexes with XRN2 (Brannan et al., 
2012; Close et al., 2012; Couvillion et al., 2012; Miki et al., 2014b), these interactions were generally 
examined through co-immunoprecipitation, leaving it unclear whether the interaction is indeed direct 
and mediated by this specific domain. The fact that the interaction surfaces of both XRN2 and XTBD 
are highly conserved (Fig. 2A), supported a conserved and direct interaction. To test this notion 
experimentally, we produced recombinant XRN2 and the XTBD-containing proteins CDKN2AIP and 
CDKN2AIPNL/C2AIL (for brevity we use C2AIL in the following) from Danio rerio (zebrafish) in E. coli 
and determined their interactions. Whereas CDKN2AIP is a tumor suppressor that can activate p53, 
C2AIL is as yet uncharacterized. When purifying the N-terminally-His6-tagged XTBD-proteins, XRN2 co-
purification was readily detectable in both cases (Fig. 3A). Similarly, human XRN2 co-purified with 
human His6-C2AIL (data not shown). To confirm that the mode of interaction between XTBD and XRN2 
was also conserved, we sought to disrupt it in the human C2AIL – XRN2 complex by mutating C2AIL 
Tyr82, which corresponds to PAXT-1 Tyr56 (Fig. S3B). Thus, we transfected human HEK293T cells with 
either wild-type or Tyr82-to-Ala mutant human FLAG-HA-C2AIL and immunoprecipitated the 
respective protein by use of an anti-FLAG antibody. Western blotting confirmed robust co-
immunoprecipitation of endogenous XRN2 with wild-type but not mutant FLAG-HA-C2AIL (Fig. 3B). 
This result confirms the specificity of this interaction and the importance of this residue for XRN2-
binding by XTBD. Finally, we showed by SEC that D. rerio XRN2 formed a stable, chimeric complex with 
human C2AIL (Fig. 3C). We conclude that XTBD constitutes a generic XRN2-binding domain whose 
function is conserved across animal phylogeny.  
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 Human C2AIL can substitute for C. elegans PAXT-1 in vivo 
To validate our insights on XTBD conservation that the in vitro and cell-based studies had generated, 
we sought to test them in vivo by expressing a codon-optimized and flag-tagged human c2ail single-
copy transgene in C. elegans paxt-1 null mutant animals. Strikingly, immunoprecipitation of FLAG-
Hs_C2AIL from paxt-1(0); hs_c2ail worm lysates co-immunoprecipitated endogenous C. elegans XRN2 
as confirmed by western blot (Fig. 3D) and mass spectrometry (data not shown). This validates the 
formation of a chimeric complex in vivo. 
Although PAXT-1 is dispensable at lower temperatures, paxt-1(0) animals arrest as L1-stage larvae 
when grown at 26°C, a phenotype that can be rescued by expression of PAXT-1_1 – 121 (Miki et al., 
2014b). Strikingly, the hs_c2ail transgenic worms similarly continue development into adulthood and 
go on to produce F2 progeny (Fig. 3E). Hence, not only the molecular but also the developmental 
function of PAXT-1 can be taken over by human C2AIL, despite the fact that these two proteins share 
only ~35% sequence identity in their XTBDs, but consistent with the good correlation of the C2AIL 
homology model with the XTBD structure (Fig. S3A, S3B).  
 
XRN2 Stability Depends on the Structural Integrity of the PBD 
We recently reported that loss of PAXT-1 in C. elegans causes a reduction of XRN2 protein but not 
mRNA levels in vivo, consistent with destabilization of the nuclease (Miki et al., 2014b). To test a 
stabilizing function of PAXT-1 towards XRN2 directly, we examined the thermal stability of 
recombinant XRN2 and its complex. For this we monitored the unfolding of the PAXT-1 – XRN2 complex 
versus XRN2 alone. Whereas XRN2 alone has an experimentally determined melting temperature Tm 
of ~31°C, the Tm of the PAXT-1 – XRN2 complex is ~55°C (Fig. 4A). This striking shift of melting 
temperatures by a ΔTm of 24°C reveals that PAXT-1 indeed has a pronounced stabilizing activity 
towards XRN2. Moreover, PAXT-1 – XRN2, PAXT-1 – XRN2ΔZLC and XTBD – XRN2ΔZLC complexes have 
measured Tm values of 55°C, 54°C, and 53°C, respectively. Hence, the major stabilizing activity of PAXT-
1 resides in the XTBD. Finally, the fact that the Tm of 31°C for XRN2 alone is close to the temperature 
at which larval arrest phenotypes in C. elegans paxt-1(0) mutants are observed (26°C) suggests the 
possibility that XRN2 destabilization in vivo occur through its unfolding and subsequent degradation. 
Previously we examined the influence of PAXT-1 on the enzymatic activity of XRN2 (Miki et al., 2014b) 
and found the PAXT-1 – XRN2 complex more active than XRN2 alone over extended periods of time. 
However, initial velocities remained unchanged in the presence or absence of PAXT-1, implying a 
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stabilizing rather than a stimulatory effect. Indeed, although closer inspection of the XTBD – XRN2 
structure suggested the possibility of a modulatory function of PAXT-1 on XRN2 activity (see below), 
examination of Michaelis-Menten enzyme kinetics failed to provide any evidence for such a function 
(Fig. S4A). To test the consequences of destabilization by temperature increase, we compared the 
activity of XRN2 in vitro at two temperatures, 25°C (default temperature of previous activity assays) 
and 30°C. We chose these two temperatures because they are within, or close to, the physiological 
range of C. elegans. [C. elegans can survive at 30°C for at least several hours, but does not procreate.] 
From the melt curve, we estimate that 45% of XRN2 would be unfolded at 30°C. Nonetheless, and 
contrary to our expectation, we found that XRN2 activity was consistently, and over extended times, 
higher at 30°C than 25°C (Fig. 4B). 
Although an increase in temperature accelerates enzymatic reaction, according to Arrhenius’ equation, 
we would expect at most a modest effect with the narrow temperature window that we used. Hence, 
we considered the possibility that XRN2 might indeed be unexpectedly stable under the conditions of 
the assay, stabilized by substrate binding. To test this, we examined XRN2 thermal stability in the 
absence and presence of the 30mer RNA substrate used for catalytic assays. This revealed a stabilizing 
effect of the substrate, which increased the Tm by 2°C to ~33°C (Fig. 4C). Although the effect was small 
relative to that seen for PAXT-1, it is above the 1°C threshold previously proposed to be significant 
(Querol et al., 1996), and it occurred reproducibly at two different substrate concentrations (data not 
shown). Moreover, it was highly specific, as inclusion of tRNA, which is not a good XRN2 substrate due 
to high secondary structure and paired 5’ terminal nucleotides (Jinek et al., 2011; Stevens and Poole, 
1995), did not increase thermal stability of XRN2. Hence, we conclude that substrate binding can 
stabilize XRN2. 
To understand the interaction of XRN2 with substrate, we superimposed the XRN1 – substrate complex 
(Jinek et al., 2011; PDB 2Y35) onto the XTBD – XRN2 structure. This revealed a crucial role of the PBD-
protruding loop in substrate binding, as its Trp670 base-stacks with three unpaired 5’- terminal 
nucleotides and His60 of α-helix 2 (Fig. 4D). Moreover, Trp670 in XRN2, as Trp540 in XRN1 (Jinek et al., 
2011), forms a steric barrier in concert with N-terminal α-helix 1 to restrict access to the active site for 
single stranded RNA. That the mode of substrate binding is indeed conserved between the two RNases 
is confirmed by the identification of a sulfate ion from the crystallization buffer of the XTBD – XRN2 
complex occupying the precise position of the 5’ phosphate of the XRN1 – RNA substrate complex (Fig. 
4D). 
From the structures of the two complexes it is thus evident that both substrate and PAXT-1 bind to the 
PBD. To determine whether this might affect PBD structure, we compared the PBDs from these two 
complexes to that of K. lactis XRN1, which was crystallized in the absence of both substrate and 
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additional proteins (Chang et al., 2011; PDB 3PIF). Strikingly, whereas the PBD is fully structured in 
XRN2 – XTBD and Drosophila XRN1, it is heavily disordered in the structure of K. lactis XRN1 and the 
domain could not be entirely built in the crystallographic model (Fig. 4E). Hence, although not a proof, 
these structures are consistent with the notion that stabilization of XRN2 is achieved through 
maintenance of the integrity of the PBD, which both XTBD- and substrate-binding can accomplish (Fig. 
4E). 
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Discussion 
Based on the recurring identification of DUF3469 domain-containing proteins in complexes that also 
contain XRN2 (Brannan et al., 2012; Couvillion et al., 2012; Miki et al., 2014b), we previously 
hypothesized that it mediates XRN2-binding. Here, we have tested this notion and demonstrate that a 
core DUF3469/XTBD domain, substantially smaller than initially predicted, mediates direct and specific 
binding to XRN2. Chimeric interactions between XTBD-containing proteins and XRN2 from different 
species in vivo and in vitro confirm the generality of this finding. Moreover, although the XRN2 
paralogue XRN1 is highly similar in sequence to XRN2, including in the PAXT-1 binding groove formed 
by the NCD2 and the PBD (Fig. S1D, S1E), binding of PAXT-1 to XRN1 is disfavored: the NCD2 of XRN1 
extends further into the groove than that of XRN2, suggesting a steric clash between this domain and 
XTBD (Fig. S1E). This is consistent with co-immunoprecipitation (co-IP) experiments, which revealed a 
specific interaction of PAXT-1 with XRN2, but not XRN1 (Miki et al., 2014b). We conclude that XTBD is 
a generic and specific XRN2 binding domain. 
Although PAXT-1 is the only XTBD-containing protein in C. elegans, many vertebrates have three such 
predicted XTBD proteins, CDKN2AIP, C2AIL, and NKRF (Miki et al., 2014b). Outside their XTBDs, these 
proteins exhibit little sequence homology, and their cellular functions, although not well characterized, 
appear distinct: Mammalian NKRF was identified as a transcriptional repressor, CDKN2AIP appears to 
function as an activator of p53 (Cheung et al., 2014; Feng et al., 2002; Hasan et al., 2002, 2004), and 
C2AIL has currently no known function. However, the strong interaction that we observe between 
XTBDs and XRN2, resistant to high salt levels and high dilution, implies that all of these proteins will 
exert at least part of their functions with or through XRN2. The ability to uncouple these proteins from 
XRN2 through a single point mutation now provides the tool to test, in future work, whether and to 
what extent this holds true for each of these proteins.  
A second implication of the stable and heterodimeric binding between XRN2 and XTBD is that 
vertebrate XRN2 can be assumed to exist in multiple complexes that occur in separate, non-
interchangeable pools, thus potentially diversifying XRN2 functions. Different binding partners may 
endow XRN2 with distinct catalytic activities, facilitate differential regulation of XRN2 through distinct 
subunits, or recruit XRN2 to distinct cellular locations. Results from immunofluorescence experiments 
on human U-2 OS osteosarcoma cell lines indeed provide circumstantial evidence for the latter, as 
XRN2 staining is observed in both nucleus and nucleoplasms, whereas NKRF locates to the nucleolus, 
from which the nucleoplasmic CDKN2AIP appears excluded (Uhlén et al., 2015). 
According to such a model of functional specialization of XRN2 complexes, XTBD serves a bridging 
function between XRN2 and specific protein domains that provide additional functionalities. As a 
complex of XRN2 with full-length PAXT-1 did not crystallize, we do not know what such functions could 
32 
 
be in the case of the PAXT-1 C-terminal sequence, which is conserved across nematodes. However, we 
may speculate that it could serve to modulate XRN2 activity or to block access of specific substrates to 
the XRN2 active site. This is because the structure of the XRN2 – XTBD complex implies that the PAXT-
1 C-terminus would be located right in front of the XRN2 nuclease cleft, and because analysis by 
PSIPRED (Buchan et al., 2013) and DisEMBL (Linding et al., 2003) suggests it to be structured (data not 
shown).  However, since we have thus far been unable to observe regulation of XRN2 activity by PAXT-
1 in vitro, it seems possible that such functions would only occur on specific substrates or under specific 
conditions that remain to be identified. 
In agreement with a more specialized role of the PAXT-1 C-terminus, it is dispensable for C. elegans 
viability (Miki et al., 2014b). Together with the fact that the heterologous human C2AIL can substitute 
for PAXT-1 in vivo, this then implies functions of XTBD beyond that of a passive XRN2 adapter. Our data 
support this function to be stabilization of XRN2 by promoting the folding of its PBD domain. The Tm is 
a measure of a protein’s thermal stability and depends on numerous molecular parameters such as 
the amino acid composition, surface hydrophobicity, number of hydrogen bonds and labile secondary 
structures such as loops (reviewed in Vieille and Zeikus, 2001). Upon XTBD-binding, 13 hydrogen bonds 
are formed, a hydrophobic patch covered and the flexibility of the PBD loop reduced. Decreased 
thermal stability of XRN2 in the absence of XTBD in vitro may then reflect decreased half-life in vivo 
(Ghaemmaghami and Oas, 2001; McLendon and Radany, 1978; Parsell and Sauer, 1989), as even 
partially unfolded proteins exhibit increased susceptibility to proteolysis (Kumar et al., 2000; Parsell 
and Sauer, 1989). This then explains how PAXT-1/XTBD binding increases XRN2 levels in vivo.  
Although PAXT-1 is expressed throughout C. elegans development (Miki et al., 2014b), its loss causes 
defects only at specific stages: when paxt-1(0) mutant animals are shifted to the restrictive 
temperature of 26°C during the L4 stage, they will continue development through adulthood and 
produce F1 progeny, which, however, will arrest at the first larval (L1) stage (Miki et al., 2014b). This 
delayed effect does not appear to simply reflect the time it takes to deplete XRN2, as L1 stage arrest 
of F1s also occurs if parental animals were already shifted to 26°C during their L1 stage (Miki et al., 
2014b). Moreover, although animals may conceivably be more dependent on XRN2 activity during 
some developmental stages than others, developmental arrest can be induced in virtually any stage 
upon direct inactivation of XRN2 (Miki et al., 2014a). Hence, we speculate that it is the stability of XRN2 
that varies with development stage. Specifically, with substrate binding conferring some stability to 
XRN2, the stabilizing activity of PAXT-1 may be more important when substrate levels are low. Thus, a 
key function of XTBD may be to preserve, rather than promote XRN2 activity, guarding enzyme not 
bound by substrate against decay to retain a constant pool of active protein.  
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Material & Methods 
 
Protein Expression and Purification 
Constructs were expressed in E. coli BL21(DE3) using a modified bis-cistronic vector from Novagen 
where XTBD-containing proteins carried an N-terminal His6-tag whereas XRN2 proteins were untagged. 
Cleared lysate was obtained by sonication and centrifugation. Target protein was purified using IMAC, 
TEV-cleavage, ion-exchange and size-exclusion chromatography. Protein fractions were subsequently 
concentrated as desired and used for crystallography or aliquoted and flash-frozen for storage. See 
Supplementary Methods for details. 
 
Crystallization, Data Collection and Structure Solution 
Protein crystallization was carried out at 20°C using the sitting-drop vapor diffusion method with a 
Phoenix robot (Art Robbins) dispensing 300 nl drops (100 nl crystallization buffer and 200 nl protein 
solution). XRN2ΔZLC − XTBD crystals, obtained in 2 M ammonium sulfate, 0.1 M Bis-TRIS pH 6.5 or 0.1 
M TRIS pH 8.5 were harvested and flash-cooled in liquid nitrogen after cryoprotection with 3.2 M 
ammonium sulfate, 0.1 M Bis-TRIS pH 6.5 or 0.1 M TRIS pH 8.5. Highest resolution data was obtained 
with a seleno-methionine derivative crystal, which diffracted to 2.85 Å at the SLS PX-II beamline 
(Villigen, Switzerland) and belonged to space group P212121 with six XRN2ΔZLC – XTBD heterodimers in 
the asymmetric unit. Diffraction data was integrated and scaled using the XDS program package 
(Kabsch, 2010) and the structure was solved by the molecular replacement method with PHASER 
(McCoy et al., 2007) using an XRN2 homology model consisting of the exonuclease core as search 
model. Phases from this solution were calculated and used for automatic model building with 
BUCCANEER (Cowtan, 2006). The XRN2ΔZLC – XTBD structure was further improved by the 
crystallographic simulated annealing routine followed by grouped B-factor refinement in PHENIX 
(Afonine et al., 2012), several rounds of manual rebuilding in COOT (Emsley et al., 2010), and 
refinement in PHENIX and BUSTER (Bricogne et al., 2011). Non-crystallographic symmetry restraints 
were used throughout the structure solution and refinement process. Model building and validation 
was carried out with the help of anomalous difference Fourier electron density maps to locate seleno-
methionine positions. The final structure was validated using COOT. Structural images for figures were 
prepared with PyMOL (Schrödinger, 2010). 
 
Thermal Shift Assay 
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A Protein Thermal Shift™ Dye Kit (Applied Biosystems) was used according to the manufacturer’s 
instruction. Two µg total protein (1 µg when mixed with substrate) was assayed in triplicates using the 
melt-curve program of a StepOnePlus™ real-time PCR system. The sigmoidal part of the melt curve 
was fitted to the Boltzman equation with the non-linear regression analysis using Microsoft Excel. 
These functions were normalized to 1, scaled for concise representation and plotted along with the 
corresponding raw-data.  
 
Real-time Exonuclease Activity Assay and Kinetic Analysis  
The kinetic assay was performed as described in Sinturel et al., (2009) with the following modifications: 
A substrate mix of RNA – DNA duplex, where the RNA is FAM-labeled whereas the DNA carries a 
quencher, and unlabeled let-7 was used at a ratio of 1:4 to increase the  dynamic range of the assay. 
Enzymes were assayed with an excess of total substrate of 5 to 200 fold. Data was subsequently fitted 
to the Michaelis – Menten-model by the least square method. 
 
Strains 
Standard procedures were used to culture the Bristol N2 wild-type, mutant and transgenic strains 
(Brenner, 1974). HW1091: paxt1-(xe5) is the null mutation described by Miki et al. (2014b). Generation 
of HW 1641: paxt-1(xe5) I; xeSi203[Ppaxt-1::C.elegans_co_human_C2AIL_FLAG_ operon_GFP_tbb-2-
3'UTR, unc-119(+)] II and HW 1644: paxt-1(xe29[I:8597012-8597014 = TAT -> GCT,  I:8597041 A -> T] 
(expressing PAXT-1_Y56A and containing a silent mutation to facilitate screening for genome editing 
events) are described in detail below. 
 
Genome Editing of C. elegans Using CRISPR-Cas9 
A suitable site for 20 nt long sgRNA was identified by considering availability of a PAM site to create a 
double strand break on the paxt-1 gene. Two complementary nucleotides were hybridized and cloned 
by Gibson assembly (Gibson et al., 2009) into pIK111, a derivative of the PU6::sgRNA backbone 
(Friedland et al., 2013; Katic et al., 2015). Furthermore, a 100 nt DNA single stranded repair oligo was 
designed with the desired point mutation and a silent mutation at the sgRNA binding site. A CRISPR 
co-conversion mix, also containing Peft-3::Cas9::tbb-2 3’ UTR (Dickinson et al., 2013), the sgRNA and 
oligonucleotide to recreate the sqt-1(sc1) mutation (analogous to (Arribere et al., 2014) ) was injected 
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into N2 animals (Katic et al., 2015). Roller progeny were cloned and their progeny were analyzed for 
desired mutations by PCR. 
 
Rescue Experiments Using MosSCI 
The paxt-1 promoter, H. sapiens C2AIL (codon-optimized + two artificial introns) coding sequence and 
tbb-2 3’ UTR sequences were cloned into pCFJ150 by Gateway cloning. An operon_GFP sequence 
between C2AIL and the tbb-2 3’UTR was included to permit visualization of transgene expression 
without altering the sequence of the encoded protein. The resulting plasmid was inserted into the 
ttTi5605 site by MosSCI (Frøkjaer-Jensen et al., 2008; Frøkjær-Jensen et al., 2012), yielding 
xeIs203[Ppaxt-1::C.elegans_co_human_C2AIL_FLAG_operon_GFP_tbb-2-3'UTR,unc-119(+)] II animals. 
The integrants were outcrossed to wild-type N2 and crossed into the paxt-1(xe5) mutant. Rescue of 
the paxt-1(0) mutant phenotype was examined as reported (Miki et al., 2014b).  
 
Cell Culture and Transient Transfection of HEK293T Cells 
Transfection and culturing of HEK293T cells were done as described in de la Mata et al. (2015). 
pIRESneo (Addgene plasmid #10822) harboring either wild type or Tyr82-to-Ala mutated Hs_C2AIL and 
pSD44 (modified Addgene plasmid #12252) expressing GFP were used for transfection. 
 
Antibodies, Co-Immunoprecipitation and Western Blot Experiments 
Antibodies, immunoprecipitation and western blotting are described in detail in the supplementary 
methods. 
 
Microscopy 
Stereoscopic images were taken with a M205 A stereo microscope (Leica, Solms, Germany). 
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Figure Legends 
 
Figure 1: Overall Structure and Domain Architecture of the XTBD – XRN2ΔZLC Complex 
(A) Schematic of the domain architecture of PAXT-1 and XRN2 and protein constructs used in this study. 
Hatched and dotted areas within NCD1 and NCD2 mark the zinc-finger and disordered loop, 
respectively.  The blow-up shows a sequence logo  (Wheeler et al., 2014) of XTBD. (B) Overall structure 
of the XTBD – XRN2ΔZLC complex as cartoon model with transparent surface for XRN2ΔZLC. Colors for 
XRN2ΔZLC and for XTBD correspond to colors in (A). (C) Cartoon representation of XRN2 (red, green and 
cyan) in complex with the XTBD (yellow).  Seleno-Methionine residues are shown as sticks with 
corresponding anomalous difference Fourier peaks in magenta (5 σ).  
 
Figure 2: Tyr56 Is Critical for Stability of the Highly Conserved XTBD – XRN2ΔZLC Interface 
(A) Surface representation of XRN2ΔZLC and XTBD structures highlighting the high degree of 
conservation of the protein – protein interface (XTBD rotated 180 ° with respect to XRN2ΔZLC). Position-
specific conservation scores computed by Consurf (Ashkenazy et al., 2010; Celniker et al., 2013) are 
displayed from white (weak to average conservation, Consurf levels 1-6) to red (most conserved, level 
9). The dashed-dotted line on XRN2ΔZLC represents the projection of bound XTBD. (B) XTBD residues 
Cys54 and Tyr56 and their interaction with XRN2ΔZLC residues. (C) Zoom-in on Tyr56, which is locked 
by Leu45 and forms a CH – π interaction with Pro656 and a hydrogen bond with the backbone carbonyl 
of Asp653. (D) Zoom-in on the Tyr56/Cys54 side chain arrangement, which allows formation of the 
isolated β-bridge between backbone atoms of Glu55 (XTBD) and Asp658 (XRN2ΔZLC). Hydrogen bonds 
are indicated by gray dotted lines. (E) Ni-NTA pull-down experiment of His6-PAXT-1 (arrow) and its 
point mutants co-expressed with XRN2 (arrowhead). XRN2 is not co-purified with His6-PAXT-1 Tyr56-
to-Ala (lane 6) and Cys54-to-Gly (lane 5) mutant proteins, where Cys54-to-Gly but not Tyr56-to-Ala 
destabilizes PAXT-1. (F) Stereoscopic images of nematodes at a magnification of 25x. C. elegans were 
grown as indicated by the scheme (above pictures). paxt-1(xe29) Tyr56-to-Ala point mutant animals 
arrest at L1 larval stage similar to paxt-1(0), whereas wild type worms continue to develop. (G) Western 
blot of 100 µg lysate from worms grown at 26°C. XRN2 levels are reduced in paxt-1(0) and paxt-1(xe29) 
mutant relative to wild-type animals. 
 
Figure 3: XTBD is a Generic Binding Adapter for XRN2 
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(A) D. rerio XRN2 (arrowhead; aa 1-803), co-purifies with D. rerio His6-C2AIL (black arrow) and D. rerio 
His6-CDKN2AIP (blue arrow), respectively. The proteins were co-expressed in E. coli and the XTBD-
containing proteins pulled down by Ni-NTA. (B) Endogenous XRN2 co-immunoprecipitates from 
HEK293T cells with wild-type transgenic human FLAG-HA-tagged C2AIL (FH-C2AIL) but not a Tyr82-to-
Ala mutant variant thereof. Immunoprecipitation occurred by anti-FLAG antibody; transfection of a 
GFP-expressing vector was used as mock control (-). Anti-XRN2 and anti-HA antibodies, respectively 
were used to detect the proteins. (C) SEC elution profiles of C. elegans XRN2 alone (blue line), and 
complexes of PAXT-1 – XRN2 (orange), XTBD – XRN2ΔZLC (yellow) and H. sapiens C2AIL – D. rerio XRN2 
(aa 1-803, purple line). (D) Human FLAG-tagged C2AIL (FLAG-Hs_C2AIL) was expressed in paxt-1(0) 
mutant C. elegans from an integrated single-copy integrated transgene and precipitated by anti-FLAG 
antibody. Western blotting of 3% lysate (Input) and 50% eluate reveals co-immunoprecipitation of 
endogenous XRN2, detected by an anti-XRN2 antibody. Non-transgenic wild-type animals were used 
as negative control. (E) paxt-1(0) mutant animals carrying the FLAG-Hs_C2AIL encoding transgenes or 
no transgene were grown as indicated by the scheme (above pictures) and imaged under a 
stereomicroscope. In the absence of the transgene, animals arrest at L1 larval stage, whereas 
expression of Hs_C2AIL permits their progression to adulthood. 
 
Figure 4: The Structural Integrity of the PBD can be Maintained by XTBD or RNA Substrate 
(A), (C) XTBD and substrate binding promote XRN2 thermal stability. Protein unfolding was recorded 
for (A) XRN2 alone (blue line), a PAXT-1 – XRN2 complex (orange line), a PAXT-1 – XRN2ΔZLC complex 
(green line), an XTBD – XRN2ΔZLC complex (yellow line), and (C) XRN2 alone or in the presence of a 
single-stranded, 5' phosphorylated substrate (purple line) or tRNA (gray line) respectively. The 
sigmoidal part of each melt curve was fitted to the Boltzman equation, normalized to 1 and scaled for 
concise representation, and plotted along with the corresponding raw-data. A right shift in the curve 
signals stabilization. Melting points (Tm), calculated as the inflection point of each curve are indicated 
by squares. The same curve for XRN2 alone is shown in (A) and (C). (B) Enzymatic activity of XRN2 at a 
substrate excess of 50x over time. Despite thermal instability, consistently higher activity is recorded 
at 30°C (dashed blue line) than at 25°C. The negative control (no enzyme) at 30°C is shown as a gray 
line. (D) XRN2 substrate binding is inferred by superposition of XTBD (yellow) in complex with XRN2ΔZLC 
(gray/red/cyan) and D. melanogaster XRN1 in complex with substrate (PDB 2Y35). Only substrate is 
shown, in stick model, for the latter, and a mFo-DFc map of the XTBD – XRN2ΔZLC complex is overlaid 
and displayed at the SO42- position only (5.5 σ). XRN2 employs the identical substrate binding 
mechanism as XRN1 by base-stacking a tri-nucleotide with its His60 and Trp670. (E) Left: Comparison 
of the PBDs of C. elegans XRN2 (cyan) in complex with XTBD (yellow, surface representation), D. 
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melanogaster XRN1 (purple; PDB 2Y35, Jinek et al., 2011) in complex with a tri-nucleotide substrate 
and K. lactis XRN1 (orange; PDB 3PIF Chang et al., 2011). Disordered regions within the K. lactis PBD 
are marked in orange dashed lines. Right: A superposition of all three PBDs including XTBD (yellow) 
and tri-nucleotide (stick-model). 
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Table I.  Crystallographic Data Collection and Refinement Statistics 
 
 XTBD-XRN2∆ZLC (Se-Met) 
Data collection  
Space group P212121 
Unit cell dimensions  
a, b, c (Å) 170.2, 200.8, 203.0 
α, β, γ (°) 90.0, 90.0, 90.0 
Resolution range (Å)a 50.0 – 2.84 (2.91-2.84) 
Wavelength (Å) 0.97796 
Completeness (%)a 94.6 (84.5) 
Redundancya 3.2 (3.1) 
Rsyma  0.126 (1.261) 
I/σ(I)a 7.1 (0.75) 
CC (1/2) (%)a 99.3 (36.5) 
Unique reflections 155519 
  
Refinement  
Rwork 0.197 
Rfree 0.221 
Resolution range (Å) 41.6 – 2.84 
Reflections (all) 155439 
Reflections (test set) 3899 (2.5%) 
Number of atoms 34653 
RMS Deviations  
Bond lengths (Å) 0.008 
Bond angles (°) 0.97 
Ramachandran plot  
Allowed (%) 99.6 
Outliers (%) 0.4 
 
a Values in parentheses refer to the highest resolution shell 
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Supplementary Methods 
 
Protein Expression and Purification 
Expression constructs were cloned into a modified bis-cistronic pCOLADuet™ vector from Novagen. 
XTBD-containing constructs were cloned into the first multi-cloning site (MSC), and thus N-terminally 
extended by a Hexahistidine (His6) tag followed by a tobacco etch virus protease (TEV) cleavage site, 
whereas the XRN2 constructs in the second MSC remain untagged. All constructs were expressed in E. 
coli BL21 (DE3). Cells were lysed by sonication and the lysate cleared by centrifugation. Immobilized 
metal affinity chromatography (IMAC) slurry (Qiagen) was used to bind the His6-tag of the target 
protein. Next, protein was eluted through cleavage by TEV (home made (Blommel and Fox, 2007). 
IMAC was repeated and the unbound fraction collected, diluted, and subjected to a Mono Q™ 5/50 GL 
(GE Healthcare) anion exchange column. Positive fractions were pooled, filtered  with a Millex-GV 0.22 
µm filter and loaded onto a Superdex™ 200 HiLoad™ 16/600 (GE Healthcare) column. Finally the target 
fractions were collected and concentrated using Millipore® Amicon® Ultra Centifugal Filter 
Concentrators with suitable pore size. 
Incorporation of seleno-methionine was done as described by Molecular Dimensions’ 
SelenoMethionine media kit, using E.coli B834 (DE3).   
 
Crystallization, Data Collection, and Structure Solution 
Protein crystallization was carried out at 20°C using the sitting-drop vapor diffusion method with a 
Phoenix robot (Art Robbins) dispensing 300 nl drops (100 nl crystallization buffer and 200 nl protein 
solution). XRN2ΔZLC − XTBD crystals, obtained in 2 M ammonium sulfate, 0.1 M Bis-TRIS pH 6.5 or 0.1 
M TRIS pH 8.5 were harvested and flash-cooled in liquid nitrogen after cryoprotection with 3.2 M 
ammonium sulfate, 0.1 M Bis-TRIS pH 6.5 or 0.1 M TRIS pH 8.5. Highest resolution data was obtained 
with a seleno-methionine derivative crystal diffracting to 2.85 Å at the SLS PX-II beamline (Villigen, 
Switzerland) and belonged to space group P212121 with six XRN2ΔZLC – XTBD heterodimers in the 
asymmetric unit. Diffraction data was integrated and scaled using the XDS program package (Kabsch, 
2010) and the structure was solved by the molecular replacement method with PHASER (McCoy et al., 
2007) using an XRN2 homology model consisting of the exonuclease core as search model. Phases from 
this solution were calculated and used for automatic model building with BUCCANEER (Cowtan, 2006). 
The XRN2ΔZLC – XTBD structure was further improved by the crystallographic simulated annealing 
routine followed by grouped B-factor refinement in PHENIX (Afonine et al., 2012) and several rounds 
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of manual rebuilding in COOT (Emsley et al., 2010) and refinement in PHENIX and BUSTER (Bricogne et 
al., 2011). Non-crystallographic symmetry restraints were used throughout the structure solution and 
refinement process. Model building and validation was carried out with the help of anomalous 
difference Fourier electron density maps to locate seleno-methionine positions. The final structure 
was validated using COOT. Structural images for figures were prepared with PyMOL (Schrödinger, 
2010). 
 
Sequence Logo 
The profile hidden Markov model (HMM) of DUF3469 from Pfam was exported and uploaded to 
Skylign.org (Wheeler et al., 2014). For concise representation, the following parameters were set: a) 
Alignment Processing to “Create HMM - remove mostly-empty columns”, b) Fragment Handling to 
“Alignment sequences are full length” and c) Letter Height to “Information Content - Above 
Background”. The resulting logo was exported without showing the gap parameters. 
 
 
Thermal Shift Assay 
In a 20 µl reaction, 2 µg of assayed protein was mixed with Protein Thermal Shift™ Dye and – Buffer 
from Applied Biosystems to a final concentration of 1x. In the presence of RNA substrate however, 1 
µg of protein was used instead to reduce the otherwise high concentrations of RNA. Purified yeast 
tRNA (Ambion™) or a 30mer XRN2 substrate, identical to that used in the kinetic assays (see below) 
were used when examining the effect of substrate binding. The reaction was prepared in a 96 well 
MicroAmp® optical microplate at 4°C and sealed with MicroAmp® Optical Adhesive Film. After 
centrifugation for 25 s at 1,000 g the plate was read in a StepOnePlus™ real-time PCR system using a 
melt curve program from 25 – 99°C. No normalizing quencher was used and reactions were run in 
triplicates. Raw data was exported and plotted using Microsoft Excel. The sigmoidal part of the curve 
was fitted to the Boltzman equation to calculate the melting point Tm using non-linear regression by 
maximizing R² and varying Tm and C. The resulting function was normalized to 1 and plotted (see 
below). Raw-data was also normalized to 1 and plotted as dashed lines. In addition, XRN2, XRN2 + tRNA 
and XRN2 + RNA curves and values were re-scaled by a factor of 1.9, 1.3, and 1.8, respectively for 
concise representation. 
 𝐹𝐹(𝑇𝑇) = 𝐹𝐹𝑝𝑝𝑝𝑝𝑝𝑝 + 𝐹𝐹𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝−𝐹𝐹𝑝𝑝𝑝𝑝𝑝𝑝
1+𝑝𝑝
𝑇𝑇𝑚𝑚−𝑇𝑇
𝐶𝐶
, where Fpre is baseline fluorescence, Fpost is maximal fluorescence, T is temperature in 
°C, Tm is melting temperature in °C and C is entalphy. 
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 Real-time Exonuclease Activity Assay and Kinetic Analysis  
The kinetic assay was performed as described in (Sinturel et al., 2009) with the following modifications: 
The RNA-DNA duplex substrate, where the RNA is FAM-labeled whereas the DNA carries a quencher, 
was diluted with fourfold excess of unlabeled 5’ phosphorylated let-7, which increased the dynamic 
range of the qPCR system. 300 fmol enzyme was assayed with varying concentrations of total substrate 
(sum of RNA-DNA duplex and let-7) in an excess from 5 to 200 fold. Each kinetic reaction was run in 
triplicates and gave 1 data point. After each data point was normalized to its baseline, the initial linear 
phase from 0 to 180 s was fitted by linear regression. The slope of this function equals the velocity at 
the corresponding substrate concentration [S]. Furthermore the average of three velocities was 
plotted over [S] and fitted to the Michaelis – Menten-model (see below) with the least-square method.  
𝑣𝑣 = 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚∙[𝑆𝑆]
𝐾𝐾𝑀𝑀+[𝑆𝑆] , where V is velocity, Vmax is maximal velocity, [S] is substrate concentration and KM is the Michaelis- 
Menten- constant. 
 
Cell Culture and Transient Transfection of HEK293T Cells 
HEK293T cells were available in our lab, checked for mycoplasma contamination and grown in DMEM-
F12 (Gibco™) supplemented with 10% (v/v) FCS and 25 U/ml Penicillin-Streptomycin (Gibco™) at 37°C. 
Prior to transfection (described in de la Mata et al., 2015) using the PEI method, 2·106 cells were plated 
on a 6 cm dish per construct and grown for one day. Each transfection was run in 2 technical duplicates 
with plasmids derived from pIRESneo (Addgene plasmid #10822) to encode N-terminally FLAG-HA-
tagged wild-type or Tyr82-to-Ala mutated hsa_C2AIL. pSD44 harboring GFP was used as mock control. 
It is modified from the pRRLSIN.cPPT.PGK-GFP.WPRE (Addgene plasmid #12252) backbone, containing 
the SV40 enhancer/early promoter driving expression of a puromycin selectable marker. Cells were 
harvested 72 h after transfection. 
 
Western Blot and Co-Immunoprecipitation Experiments 
Worm lysates were prepared by douncing harvested worms with 150 pestle strokes in extraction buffer 
(50 mM HEPES, pH 7.4, 50 mM KCl, 5 mM MgCl2, 0.1% w/v Triton X-100, 10% w/v Glycerol) finalized 
with 7 mg protease inhibitor (Roche complete EDTA-free), 2 µl 1 M DTT and 10 µl 100 mM PMSF per 
ml extraction buffer. The lysate was cleared by centrifugation at 16,000 g for 20 min and protein 
concentrations of the lysates were measured using Bradford reagent (Bio-Rad Protein Assay). 
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Subsequently, 100 µg of lysate were loaded and separated by a Bis-TRIS SDS-PAGE 4 – 12% gradient 
gel (NuPAGE® Life Technologies). Proteins were then blotted on a PVDF membrane using standard 
procedures. Antibodies against XRN2, PAXT-1 (Miki et al., 2014) and FLAG-tag (Monoclonal ANTI-FLAG® 
M2-Peroxidase, Sigma) were used in a 1:500, 1:500 and 1:2000 dilution, respectively. Horseradish 
peroxidase-conjugated antibodies (GE Healthcare, Little Chalfont, UK) were used for detection, except 
for FLAG (see above). For IP experiments, 3 mg lysate was incubated with 40 µl magnetic anti-FLAG 
bead slurry (Sigma. Cat # M8823) in 1 ml finalized extraction buffer for 2 h on the rotating wheel at 
4°C. Then beads were washed 4 times with 600 µl extraction buffer followed by 1 h elution on a vertical 
shaker (4°C) with 40 µl of 1 µg / µl FLAG peptide. 
Immunoprecipitation of FLAG-HA-tagged Hs_C2AIL was performed using Anti-FLAG M2 Magnetic 
Beads (Sigma. Cat # M8823) as described in de la Mata et al. (2015). For this, 2·106 transfected HEK293T 
cells per IP and construct were washed with 4 ml cold PBS, harvested and lysed in 500 µl lysis buffer 
(50 mM TRIS pH 7.5, 150 mM NaCl, 1% v/v TritonX-100, 1 mM EDTA, 1x EDTA-free Roche cOmplete 
Protease Inhibitor Cocktail) and incubated for 30 min on ice. Subsequently, the lysate was cleared by 
centrifugation at 16,000 g for 10 min. Per IP, 40 µl of bead slurry (see above) was washed twice with 
cold TBS (50 mM TRIS pH7.4, 150 mM NaCl), added to the lysate and filled to 1 ml final volume with 
TBS. After 2 h of incubation on the rotating wheel, beads were washed three times with 400 µl TBS 
and boiled at 70°C for 10 min in 40 µl SDS loading buffer for western blot analysis detecting the 
transgene with anti-HA antibody (1:1000 dilution; clone 3F10, Roche). Human XRN2 was detected as 
described in Miki et al. (2014). 
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2 XRN2 Processively Degrades miRNAs Under Single Turnover 
Conditions 
The XRN2 paralog D. melanogaster XRN1 was shown to processively degrade 5’ 
monophosphorylated RNA molecules under single turnover conditions (Jinek et al., 2011). In 
contrast, Rat1p (yeast XRN2) seems to processively degrade RNA molecules only in complex with its 
interaction partner Rai1p, despite extensive sequence and structural similarities to XRN1 (Jinek et al., 
2011; Kenna et al., 1993; Stevens and Poole, 1995; Xiang et al., 2009). On the other hand, XRN2s from 
other species have not been investigated in respect to their mode of catalysis. Thus, questions of how 
C. elegans XRN2 executes processive substrate decay remains to be analyzed. Hence, we checked for 
processive catalysis of recombinant C. elegans XRN2 under single turnover conditions. For this, 50 
pmol synthetic 5’-monophosphorylated let-7 were labeled on the 3’-end with equimolar amounts of 
pCp using T4 RNA ligase. Subsequently, the substrate was spin-column purified and adjusted to 0.5 
nM radiolabeled substrate using the scintillation counter. For each reaction, 1 µl labeled substrate 
was used, corresponding to 0.5 fmol, and incubated with 90 fmol of recombinant enzyme at 25 °C. 
Of note, 3’-end labeling depends on an inefficient enzymatic ligation reaction and therefore a 
considerable amount of unlabeled substrate is present in each reaction. Finally, the reaction mix was 
resolved with an 8 M urea PAGE-gel and the RNA detected by autoradiography. Remarkably, for 
XRN2, without being complexed by PAXT-1, processivity similar to XRN1 was observed for let-7 decay 
in time course experiments (Figure 4). No intermediates are detected, as degradation bands for full 
length XRN2 (XRN2_fl) and XRN2 lanes represent pCp (determined in other experiments, data not 
shown). In contrast, previous results show, that Rat1p needs to be in complex with Rai1 to achieve 
similar results (Xiang et al., 2009). However earlier experiments with Rat1 were performed with much 
longer substrates and potential secondary structure elements might have inhibited processivity.  
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Figure 4: Shown is an autoradiography of the turnover of 0.5 fmol 3’- labeled let-7 miRNA comparing full length 
XRN2 (XRN2_fl, residues 1 – 975) and XRN2 (residues 1 – 821) over a period of 15 minutes at indicated times. 
Moreover catalytic dead XRN2 (XRN2*) of both constructs, buffer components (NC, negative control) and a C. 
elegans worm lysate were tested for activity and incubated for 15 min. The final reaction product for XRN2_fl 
and XRN2 corresponds to pCp (arrow/schematic). 
 
While activity and processivity is maintained by C. elegans XRN2 alone under single turnover 
conditions, we were wondering if PAXT-1 could influence the enzymatic activity of XRN2 under 
multiple turnover conditions. For this we followed its enzymatic activity in real-time in presence or 
absence of PAXT-1 as described by Sinturel and colleagues (Sinturel et al., 2009). In short, a 30 nt RNA, 
coupled to a fluorophore (FAM) at its 3’-end, is hybridized with a 17 nt DNA primer harboring a 
quencher (TAMRA) at its 5’-end. Upon catalysis, the DNA primer is dislodged and fluorescence of 
released single nucleotide-fluorophore conjugates are measured over time (Figure 5A). Of note, it 
cannot be excluded that the RNA – DNA duplex substrate affects the kinetic behavior of the enzyme 
as it relies on primer dissociation and therefore deviates from a true single stranded RNA catalysis. In 
a multiple-turnover setup with 50 fold excess of RNA substrate (DNA primer hybridized in two-fold 
excess in respect to RNA), we followed RNA decay over 1 h in presence or absence of PAXT-1 (Figure 
5B). Whereas the PAXT-1 – XRN2 complex degrades approx. 58% (+/- 0.3%) of the substrate after 3600 
s, XRN2 alone degrades approx. 43% (+/- 1%) in the same time, so that both reactions are in multiple-
turnover conditions for the entire measurement (published in Miki et al., 2014b). Interestingly, PAXT-
1 – XRN2 complexes seem more active after approx. 1000 s (Figure 5B). However initial velocities 
(initial 150 s) of XRN2 and PAXT-1 – XRN2 complex are equal, indicated by equal slopes (Figure 5B, 
inset). Thus, higher activity of the PAXT-1 – XRN2 complex is not due to stimulation of enzymatic 
activity of XRN2 by PAXT-1, but rather through the stabilizing effect of PAXT-1 on XRN2. Yet, the 
assayed RNA substrate is only 30 nt of length and we cannot rule out influences of PAXT-1 on XRN2 
catalysis on larger substrates.  
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 Figure 5: A, Schematic shows the principle of the real time degradation assay for 5’  3’ exoribonucleases. B, 
Shows the kinetic behavior of PAXT-1 – XRN2 complex (orange line) in comparison with XRN2 alone (blue line), 
nuclease dead complex (black line) and mock control (gray line) using 10 nM protein and 500 nM substrate in 
multiple turnover condition over 3600 seconds. The inset magnifies the initial velocity of the reaction. 
 
3 No Detection of MiRNA Release Off AGO with Recombinant XRN2 in 
vitro 
Previously, Chatterjee et al. (2009) showed that C. elegans lysates are capable of releasing the 
miRNA let-7 off immunoprecipitated ALG-1/2 complexes and upon depletion of XRN2 by RNAi, 
release activity of these lysates was reduced (see above). So we were curious to see if XRN2 and its 
complex with PAXT-1 has releasing capabilities in vitro. For this we incubated co-immunoprecipitated 
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miRNA – ALG-1/2 complexes from C. elegans lysates with recombinant XRN2 or PAXT-1 – XRN2 
complex and measured let-7 retained on ALG-1/2 by qPCR. To account for potential losses of miRNAs 
during RNA extraction, 3 fmol of an unrelated rat miRNA, miR-132, was spiked-in and used to 
normalize for let-7 levels using a standard curve. Release of let-7 could be detected on ALG-1/2 
complexes incubated with worm lysates (Figure 6A), whereas signals similar to input were detected 
when incubated with full length XRN2 (XRN2_fl), XRN2 (residues 1 – 821), PAXT-1 – XRN2 and XTBD 
– XRN2 complexes (Figure 6A and C). To confirm qPCR results, 50% of the release reaction mix was 
analyzed using northern blot optimized for small RNA detection (Pall and Hamilton, 2008). There, 
extracted RNAs are separated by an 8 M urea PAGE-gel, transferred (blotted) and cross-linked to a 
membrane, followed by hybridization with a complementary 32P labeled nucleic acid probe. This 
signal is then detected using autoradiography. Similar to the qPCR assay, loss of RNA, due to 
extraction and handling procedures, was controlled for by spike-in of 3 ng yeast leucine tRNA 
(tRNALeu). When probing release reactions of lysate and full length XRN2 (XRN2_fl) with an α-let-7 
probe by northern blot, observations made by qPCR (Figure 6A) were confirmed (Figure 6B). Taken 
together, no release activity could be detected for recombinant XRN2 nor in complex with PAXT-1. 
Thus, other factors within the worm lysate seem to mediate release activity but could potentially be 
linked with XRN2. This could explain partial loss of release activity upon XRN2 RNAi.  
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 Figure 6: A and B, Shown is the fold change and northern blot of co-immunoprecipitated ALG-1 and -2 bound 
let-7 incubated with buffer (neg. ctrl), C. elegans N2 worm lysate or full length XRN2 (XRN2_fl) for 15 min at 25 
°C compared to input. Samples were quantified using a standard curve (blue bars) and normalized to spiked-
in mir-132 (red bars) to correct for losses during RNA purification. Plotted values represent the mean ± standard 
deviations from three technical replicates (n = 3). C, Repitition of the assay from A, at which also PAXT-1 – XRN2 
and XTBD – XRN2ΔZLC (deletion of the zinc-finger, loop and C-terminal tail) complexes were tested for release 
activity. 
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III Discussion 
With the rapid discoveries of new RNA species and their respective functions, scientists became 
increasingly interested in RNA nucleases as these are capable to process, decay or mediate function 
to RNAs. Thus, a growing number of new nucleases or proteins harboring conserved RNase folds are 
discovered, such as AGO or Dicer. Although new multiple sequence alignment algorithms based on 
probabilistic models, such as the Hidden Markov model, can help such discoveries (Finn et al., 2011, 
2014), conservation of the primary amino acid sequence is lower than its three dimensional fold. 
Thus X-ray crystallography of proteins involved in the RNA metabolism made important 
contributions in identifying new RNases or RNase domains, such as AGO, spliceosome component 
Prp8 or NMD factor SMG6, and their molecular mode of action (Glavan et al., 2006; Pena et al., 2008; 
Song et al., 2004).  
 
Functional Implications Based on XRN Structures 
Up to now, structures of yeast and C. elegans XRN2 as well as K. lactis and D. melanogaster XRN1 are 
solved and elucidated the substrate binding mode as well as the structural elements mediating 
processivity for this class of enzymes. However, there are observed discrepancies of RNA decay 
between XRN1 and XRN2, which cannot simply be explained by their respective structures. 
Structural analysis of the XRN1 – substrate complex revealed a π – π base stacking mode for 
substrate binding formed by residues His41 and Trp540 as well as the Brownian ratchet-like mode 
for processive degradation, which relies on α-helix 1 and a conserved loop harboring Trp540 (Jinek 
et al., 2011). In line with our structural data and comparison to Rat1p, XRN2 seems to use the same 
substrate binding mechanism as key residues and structural features are conserved and electron 
densities from sulfate ions (component within the crystallization buffer) are detected at the substrate 
5’ phosphate position. Upon degradation of structured substrates, such as stem-loop containing 
RNAs, however, stalling of XRN2 was observed (Xiang et al., 2009). In contrast, such substrates are 
efficiently degraded by XRN1, with only G-quartet tracts harboring RNAs and some viral RNA being 
capable of inducing stalling (Chapman et al., 2014; Poole and Stevens, 1997). Thus an unwinding 
mechanism for XRN1 is proposed, by which the conserved loop and α-helix 1 form a small entrance 
allowing for single stranded substrate only and thus acting as a steric barrier. Either unwinding is 
conveyed actively by substrate translocation or simply by thermal breathing of the substrate, as it is 
threaded through the steric barrier to access the nuclease cleft. It thus is an extended mechanism of 
the Brownian ratchet model and processive substrate degradation (Jinek et al., 2011). It is puzzling, 
however that studies from yeast show XRN2 degradation to be limited by RNA secondary structure 
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elements, but all structural features responsible for processivity and duplex unwinding are present 
in XRN2 as well. It is worth mentioning, that XRN turnover studies do not use identical substrates 
consistently, nor turnover conditions. Studies on XRN1 from Jinek et al. were performed under single 
turnover conditions, with a large excess in enzyme concentration and so did Xiang et al. for yeast 
XRN2 with yet longer substrates. Our studies suggest a processive activity for XRN2 in multiple 
turnover conditions for small sized substrates such as miRNAs, even without being in complex with 
PAXT-1. Thus it remains to be seen, if there are indeed differences in substrate degradation on the 
molecular level between XRN1 and XRN2, and if, it would be interesting to pin point these differences 
on a structural level.  
Strikingly, the XTBD – XRN2 interface is mainly formed by the conserved loop, which would suggest 
an influence on XRN2’s catalytic activity. Yet, we do not observe any alterations in XRN2’s kinetic 
behavior in presence or absence of PAXT-1, but support of RNA binding and/or degradation of 
structured/longer substrates by PAXT-1 cannot be excluded. Conversely, PAXT-1 might as well 
regulate XRN2’s activity by restricting for certain substrate types. Unfortunately, thorough 
biochemical analysis of XRN2 substrate degradation is sparse, which might be due to the fact, that 
production of larger and structured high quality RNA molecules harboring desired modifications still 
pose a huge problem. However those studies are needed and could help to gain insights of how this 
molecular machinery works. A less appealing hypothesis would suggest XRN2 to be an ordinary 
degradation machine, which has to be kept in check by supporting cellular factors. Then XRN2 would 
possibly acquire specificity by localizing and limiting it to certain substrates. 
Compared to XRN1, XRN2 acts on a diverse spectrum of substrate classes and takes part in 
processes like transcription termination and miRNA release off AGO. Thus, it could well be, that such 
specialized functions are reflected on the structural level. One of the most prominent structural 
feature of XRN2 is its tower domain. It is a long α-helix spanning from the bottom through the 
molecule and well above the globular surface, thus mainly contributing to the unique shape of XRN2 
(Xiang et al., 2009). The tower domain makes important contributions to substrate binding/access 
and stability (Jinek et al., 2011; Xiang et al., 2009). However it is unlikely that either of these 
contributions require the tower domain’s extended length. Remarkably, the tower domain of XRN1 
is smaller and the XRN1 molecule adapts a more globular shape through its additional domains than 
XRN2 does. Hence it seems unlikely, that such a prominent shape is evolutionary conserved without 
any functions attributed to it. As XRN2 is involved in transcription termination in a model by which 
RNAPII is sterically displaced by XRN2, it is tempting to link this function to the tower domain. While 
approaching RNAPII, which is significantly bigger than XRN2, through substrate degradation, the 
tower domain could function as a battering ram for displacement of RNAP II. Hence the extended 
length of the tower domain coupled with XRN2’s catalytic activity would increase the “power” 
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available for this process. But maybe XRN2 doesn’t displace RNAP II directly, as suggested by the 
torpedo model, but uses the tower domain as an extension to kick off certain subunits bound to 
RNAP II’s tail. This idea is especially interesting, as RNAP II could be loaded with specific sets of factors 
regulating the transcription of specific genes and XRN2 might reach only subunits bound to specific 
interfaces of RNAP II due to the length of its tower domain. As a consequence, termination of 
transcription by XRN2 could be controlled by such factors and add another layer of regulation. 
 
The Subunits of the XRN2 Nuclease: What, Where, Why? 
In the past, XRN2 has been studied thoroughly in yeast, elucidating many substrates and functions, 
but just recently it became apparent, that XRN2 exists in a tight complex with a single additional 
subunit. Surprisingly, its paralogue XRN1, despite interacting with many proteins, was not found to 
form a similar nuclease complex. Two crystal structures of an XRN2 complex, from yeast and C. 
elegans, are available to date (Xiang et al., 2009; this study). Strikingly, both subunits, Rai1p and PAXT-
1 from yeast and C. elegans, respectively, bind to different XRN2 interfaces and share no similarities. 
In contrast they do share their function in stabilization of XRN2 through binding. Moreover Rai1 was 
shown to enhance nuclease activity of XRN2, whereas no such effect could be attributed to PAXT-1 
(Xiang et al., 2009; Xue et al., 2000). It is however unclear, how Rai1p stimulates XRN2, since it binds 
to the bottom of XRN2, far away from the nuclease cleft. One explanation could be that previous 
observations of increased activity of Rai1 – XRN2 complexes are merely mediated by an increased 
stability of the complex rather than increased catalytic activity. This notion is supported by 
observations of C. elegans XRN2 complexes, where real-time turnover analysis revealed increased 
activity over time for PAXT-1 – XRN2 complexes compared to XRN2 alone, but Michaelis-Menten 
kinetics analysis thereof revealed no change in catalytic activity. Therefore it was concluded, that 
increased activity mediated by PAXT-1 was due to its stabilizing function towards XRN2. Moreover, 
questions, of how XRN2 stabilization through binding to two different interfaces is mediated, remain. 
PAXT-1 forms a tight complex with XRN2 through a yet small interface of approx. 1000 Å² close to the 
substrate binding site, but makes significant contributions to complex formation (PISA score = 1) 
(Krissinel and Henrick, 2007). Rai1p’s interface however, scatters around the bottom of the nuclease, 
totaling to approx. 800 Å² and PISA interface analysis scores the Rai1 – XRN2 interface to be 
insignificant (Krissinel and Henrick, 2007; Xiang et al., 2009). Curiously, biochemical data from yeast, 
XRN2 purifications readily detect Rai1p bound to XRN2 and the complex is regarded stable (Kenna 
et al., 1993; Stevens and Poole, 1995; Xiang et al., 2009). Hence, direct comparison of the stability of 
PAXT-1 – XRN2 and Rai1p – Rat1p complexes as well as their stabilizing function could shed light on 
these discrepancies.  
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The crystal structure of the C. elegans XRN2 nuclease complex was solved using a construct 
containing only the N-terminal XTBD of PAXT-1, whereas the remaining C-terminus is missing. 
Bioinformatics analysis predicts a structurally well-ordered PAXT-1 C-terminus, however sequence 
alignments do not identify any known domains. It is tempting to imply RNA-related functions for this 
C-terminus, such as RNA-binding or substrate specificity, especially since structural data suggests its 
location just in front of the nuclease cleft. Therefore structural determination of the PAXT-1 C-
terminus alone could give further insights to PAXT-1 function and how this relates to XRN2.  
As PAXT-1 was recently identified as a subunit in the XRN2 nuclease complex, available data is 
concerned with its function related to XRN2. Nevertheless it might well be, that PAXT-1 has additional 
functions independently of XRN2, which are yet to be discovered. However, recent results show a 
direct relationship on protein stability for PAXT-1 and XRN2 as knock-down of either subunit of the 
PAXT-1 – XRN2 complex results in loss of the other, with mRNA levels being unaffected. Therefore 
dissecting any independent function of PAXT-1 seems difficult. Moreover production of recombinant 
PAXT-1 failed, as it seems unstable in high dilution in vitro. 
From an evolutionary perspective, PAXT-1 homologs are only found in nematodes, whereas the 
XTB domain is readily detected in proteins from metazoans and ciliates (Pfam DUF3469). It is puzzling 
though, that yeast lack proteins with an XTBD completely. Whether yeast XRN2 is intrinsically more 
stable than its metazoan counterpart or Rai1 has indeed similar stabilizing capabilities as PAXT-1 
(discussed above) remains to be tested. Also, it could very well be, that the XTBD evolved besides the 
existing Rai1 and gradually replaced it, as it turned out to be more stable and more suitable as an 
adapter. Conversely, the Rai1 – XRN2 interaction also couples two enzymatic activities plus 
stabilization. In certain situations this enzymatic coupling is maybe undesirable, as potential 
protection of an RNA by a 5’- trisphosphate would be a substrate for the Rai1 – XRN2 complex. 
Moreover, it could be that other functions than pyrophosphatase activity became increasingly 
important, such as substrate specificity, and displaced Rai1 with XTBD interaction/stabilization. 
Interestingly, alignment algorithms predict three different XTBD-containing proteins in mammals, 
in contrast to only one found in nematodes (PAXT-1). An enticing model could be, that XRN2 is 
capable of acquiring additional functionality by complex formation with different XTBD-proteins. 
Especially NKRF and CARF are not well characterized, functionally nor structurally, and their domain 
architecture is largely undetermined, apart from their predicted XTBD and RNA binding domain. 
Moreover, biochemical studies show PAXT-1 and XRN2 to form a strong complex, as this complex 
resists disruption in high salt environments and high dilutions. Hence, it is hard to imagine how XRN2 
subunits will be interchanged within the cellular environment. Either different XRN2 complexes are 
formed co-transcriptionally/co-translationally or there is an active exchange mechanism facilitating 
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loading/unloading of different XTBD-containing subunits. The first hypothesis is particularly 
interesting, as it permits the cell to use the regulatory machineries during gene expression to time 
and setup XRN2 complexes with different functionalities. Yet, it is possible that other proteins interact 
with XRN2 independently of an XTB domain. Conversely, XTBD-proteins may also recruit and bind 
additional subunits in an XRN2 complex. Considering all these possibilities, XRN2 possibly gains 
many of its specialized functions directly or indirectly by complex formation with XTBD- proteins. As 
now the XTBD key interface residue Tyr56 was identified, mutations will thus allow further 
dissections of XRN2’s complex functions and potential regulation. Also elucidating the interactome 
of the XTBD-proteins could shed more light on potential functions, substrates and subcellular 
localization related to XRN2 
 
XRN2 and the Mysterious Release Factor 
Previously, Chatterjee and colleagues observed an unusual function of XRN2 with no obvious link 
to catalysis. When co-immunoprecipitated miRNA – AGO complexes were incubated with XRN2 
depleted C. elegans lysates more miRNAs remained bound to AGO compared to wild type lysates. 
This led to the hypothesis, that XRN2 is involved in mediating miRNA release off AGO. However 
testing for potential release activity in vitro using recombinant XRN2 and PAXT-1 – XRN2 complex, 
no such activity was observed. This suggests, that XRN2 guides releasing factors to AGO complexes 
rather than exhibiting release activity itself. As pointed out earlier, XTBD-proteins could serve as 
protein scaffolds, recruiting more subunits to XRN2, hence also serving as a release factor binding 
platform. Thus it would be interesting to create PAXT-1 C-terminus deletion worm lines and check if 
similar release defects occur as observed for XRN2 knock-downs. However, off-target effects of XRN2 
RNAi or secondary effects thereof, such as reduced stability of yet unknown proteins, could have led 
to wrong assumption of an XRN2 mediated miRNA unloading off AGO and this mechanism might be 
completely unrelated to XRN2. 
 
Implication for XRN2 in Human Diseases 
XRN2 and its important functions are well studied in various model organisms, such as yeast and 
C. elegans. It plays crucial roles in the RNA metabolism as described earlier, however studies 
investigating its physiological role in humans lack behind. Interestingly, it could recently be shown, 
how hepatitis virus C (HCV) uses endogenous miRNAs to prevent degradation of its RNA genome by 
XRN2 as well as XRN1 (Li et al., 2015; Sedano and Sarnow, 2014). HCV’s RNA genome harbors binding 
sites at its 5’-end for liver miRNA miR-122, which forms a duplex protecting for potential degradation. 
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It is however not well understood, how a predominantly nuclear nuclease like XRN2 acts on HCV’s 
cytoplasmic genome, especially since its 5’-end harbors a triphosphate group. 
Moreover, XRN2 is found to be amplified in breast cancer coinciding with amplifications of 
CDKN2AIP (Cerami et al., 2012; Eirew et al., 2014; Gao et al., 2013). Also, mutations of cis-acting 
regulatory elements in spontaneous lung cancer of nonsmokers lead to increased XRN2 mRNA levels. 
Accordingly, XRN2 is implicated in proliferation and differentiation of lung epithelial cells (Lu et al., 
2010). Remarkably, staining of CDKN2AIP and NKRF in human U-2 OS osteosarcoma cells reveal 
specific localization to the nucleus and the nucleolus, respectively (Uhlén et al., 2015). This underlines 
the hypothesis, of XRN2 forming multiple complexes to execute its diverse functions at different 
subcellular compartments. 
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